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ABSTRACT 
 
Advancements in our understanding of the molecular causes of cancer have led to 
the therapeutic targeting of key enzymes involved in cell growth and proliferation. Despite 
these advancements, cancer is expected to be the leading cause of death in the U.S. by the 
year 2035. Over the same period, the number of new cases globally is projected to rise by 
about 70%, necessitating an urgent need for the exploration of novel targets and 
therapeutics for the treatment of cancer. Of the drugs in current clinical use, kinase 
inhibitors have been the most successful forms of targeted therapy for a select group of 
cancers. However, a comprehensive understanding of the biological roles of individual 
kinases is necessary for therapies to be effective in a majority of cancers. The development 
of selective kinase probes and inhibitors, is, therefore, essential, for continued 
improvement in cancer chemotherapy. Additionally, the identification and exploration of 
non-kinase targets will be indispensable in adding to the toolbox of effective anti-cancer 
agents. To aid in our understanding of the molecular causes of cancer and to increase the 
number of tools available for its treatment, we aimed to develop inhibitors for critical 
proteins involved in phospho-signaling pathways. 
Our studies began with the development of a selective inhibitor of the fusion 
protein, Bcr-Abl, which is the primary driver of Chronic Myelogenous Leukemia (CML). 
Most current FDA-approved drugs are ineffective against a resistant form of CML bearing 
a T315I mutation in the kinase domain of Bcr-Abl. While one approved drug, Ponatinib, is 
effective in the treatment of resistant CML, it displays life-threatening, and often, fatal 
toxicity owing to its promiscuity at inhibiting a multitude of kinases. Through a hypothesis 
based on the prevailing model of selectivity for the Abl kinase domain, we developed a 
library of small molecules and identified a compound with high potency for both the wild-
type and mutant forms of Abl. The potency was comparable to that of Ponatinib, with a 
significantly improved spectrum of selectivity.  
xiii 
 
An alternate, non-kinase, and under-explored target for the treatment of CML and 
other cancers is the adaptor protein Grb2. Current inhibitors of Grb2 suffer from poor 
cellular efficacy, which is likely a consequence of most such inhibitors being primarily 
based on a single scaffold. Our efforts for targeting Grb2 centered on the hypothesis that 
utilizing conformational constraint for inhibitor development could lead to compounds 
with increased potency due to a lowered entropic cost of binding. Through the systematic 
development of conformationally constrained cyclic peptides, we identified a novel 
scaffold for the inhibition of Grb2 with in cellulo efficacy in a CML cell line.  
Lastly, while protein kinases have been traditionally targeted with small molecules 
directed to their ATP-binding site, targeting the peptide substrate-binding site of kinases 
offers an attractive alternative with several advantages. The nature of the substrate-binding 
site, however, typically requires the development of linear peptidic inhibitors that lack 
potency and suffer from poor cell permeability and stability. Our efforts attempted to 
circumvent the problems associated with substrate-competitive inhibitors by covalently 
inhibiting the target Akt1 kinase. Our lead compound could prove a valuable tool for the 
delineation of the roles of specific isoforms of the Akt kinases.  
As a whole, results from this work should advance the development of potent and 
selective inhibitors and aid in the understanding of signaling pathways involved in cancer. 
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CHAPTER I 
Targeted Therapy in the Treatment of Cancer 
1.1. Abstract 
The last two decades have witnessed tremendous advancements in our 
understanding of the molecular causes of cancer and targeted therapy directed towards 
certain types of cancer. Despite these advancements, cancer remains the second most 
common cause of death in the U.S. (after heart disease) and is expected to be the leading 
cause by the year 2035. Over the same period, the number of new cases globally is 
projected to rise by about 70%, necessitating an urgent need for the exploration of novel 
targets and therapeutics for the treatment of cancer. This chapter provides a brief overview 
of the developments that led to our current understanding of the molecular causes of cancer. 
Furthermore, it details some of the key signaling pathways involved in cancer and offers 
insights into the limitations of our current understanding of these pathways as well as 
strategies for the development of novel cancer therapeutics.  
1.2. Molecular Causes of Cancer 
In 1911, Peyton Rous described an agent isolated from chicken tumor cells that, 
when injected in healthy chickens, caused the growth of tumors.1 His observations, though 
seminal, were looked upon with skepticism, since at the time, cancers were not known to 
be transmissible.2 His work did, however, initiate one of the first inquiries into the cause 
of cancer and 40 years later it was incontrovertibly proven that the causative agent observed 
by him was a virus, which could, in fact, cause the growth of tumor cells.3 By the 1940s, 
through epidemiological and experimental data, it was well understood that cancers could 
be initiated by exposure to radiation and certain chemicals. However, the exact mechanism 
through which such exposure caused cancer was unclear.4  
Around the same time, the modern era of cancer chemotherapy was initiated 
through the findings of Louis Goodman and Alfred Gilman investigating the therapeutic 
potential of chemical warfare agents. To assess the cytotoxic effects of nitrogen mustards 
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on cancer cells, a single mouse transplanted with a tumor was administered with, what was 
then only disclosed as, ‘Chemical X’.5 Remarkably, regression of the tumor to undetectable 
levels was observed, and the mouse lived eighty-four days after implantation. Studies in 
several different tumor-bearing mice, however, revealed that some, but not all mice, 
showed tumor regression to various extents. Their fortuity and success were reflected upon 
by their colleague, Thomas Dougherty in a correspondence with Gilman; “… the very first 
mouse treated turned out to give the best result … in most of the murine leukemias, 
particularly those which metastasize readily, we frequently obtained no effect at all. I have 
often thought that if we had by accident chosen one of these leukemias, in which there was 
absolutely no therapeutic effect, we might possibly have dropped the whole project”.5 In 
addition to paving the way for cytotoxic chemotherapy, these initial studies led to the key 
observation, articulated above by Thomas Dougherty, that the efficacy of chemotherapy 
was not universal and variations in response existed in different tumor types.5-6  
The idea that all cancers are not alike led to a massive effort in trying to understand 
the underlying cause of different cancers; an effort that continues to this day. The discovery 
that Chronic Myelogenous Leukemia (CML) arises from a shortened chromosome 227-9, 
and the subsequent discovery of proto-oncogenes10-11 led to a fundamental change in the 
understanding of how mutations and translocations lead to cancer and genetic 
abnormalities in other cancers were studied. By the 1990s, advances in molecular biology 
led to the identification and mapping of several signaling pathways involved in tumor cell 
growth and set the stage for targeted therapy in cancer.  
1.3. Phospho-Signaling Pathways Involved in Cancer 
One of the most important pathways involved in cell growth is the Ras-signaling 
pathway. The best-characterized model of this pathway involves a linear signaling cascade 
from the epidermal growth factor receptor (EGFR) to transcription factors. By the late 
1980s, though it was well understood that the GTPase, Ras, was dependent on the 
activation of EGFR, the exact mechanism through which this occurred was unclear. The 
key missing components were identified in rapid succession in the early 1990s with the 
characterization of the adaptor protein Grb2, and the guanine-nucleotide exchange factor 
Sos.12 (The role of Grb2 within this pathway is discussed in depth in Chapter III.) 
Receptor activation and phosphorylation leads to the recruitment of the Grb2-Sos complex 
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from the cytosol to the membrane. The localization of Sos to the membrane leads to the 
conversion of membrane-bound Ras from its inactive, GDP-bound state, to its active, GTP-
bound state. This triggers the activation of an entire signaling cascade through the 
phosphorylation of downstream kinases Raf, Mek, and Erk, ultimately resulting in cell 
growth and proliferation.  
Approximately 30% of all tumors have activating Ras mutations making them one 
of the most common genetic causes of cancer.13 Activating Ras mutants contributes 
significantly to deregulated cell growth and, even tumors that lack Ras mutations, activate 
and deregulate the Ras-signaling pathway through other means.14 The early identification 
of the entire pathway from the cell surface to the nucleus and its involvement in cell growth 
and proliferation made it an excellent candidate for therapeutic intervention in cancer.  
1.4. Efforts at Targeting Ras 
The Ras proteins have been extremely difficult to target, and no effective targeted 
therapy exists. The development of guanine-nucleotide mimics directly targeting the 
binding site have been deemed unfeasible owing to the high affinity (picomolar) of Ras for 
both GDP in the inactive state and GTP in the active state, coupled with millimolar 
concentrations of these nucleotides in cells.15 Some recent success has been achieved, 
however, in covalently targeting a mutant form of K-Ras (G12C)15-16 and in identifying 
low-affinity (high micromolar) allosteric inhibitors of K-Ras.17-18 Further development of 
allosteric inhibitors is needed, however, for them to be viable therapeutic agents.  
In lieu of a direct-targeting approach, disruption of the post-translational 
farnesylation of Ras at its C-terminus, and preventing its subsequent membrane 
localization, was attempted. The 1990s subsequently witnessed a massive effort by 
pharmaceutical companies to develop inhibitors of farnesyltransferase (the enzyme 
responsible for the post-translational modification) based on impressive results in pre-
clinical models.19 This effort was ultimately unfruitful in terms of efficacy in clinical trials 
as inhibition of farnesyltransferase led to the prenylation of Ras through the alternate 
mechanism of geranylgeranylation by the enzyme geranylgeranyltransferase. Furthermore, 
it was believed that the pre-clinical success of farnesyltransferase inhibitors was due to the 
non-specific inhibition of farnesylation of proteins other than Ras.14, 19-20 
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With little success in directly or indirectly targeting Ras proteins, other methods to 
target the Ras-signaling pathway have been attempted which have coincided with the 
concomitant rise of Bcr-Abl inhibitors in the treatment of CML. 
1.5. Current Targeted Therapy  
CML, discussed in detail in Chapter II, is one among a very small group of cancers 
that is driven by a single genetic abnormality. The shortened chromosome observed in 
CML is caused by a reciprocal translocation t(9;22)(q34;q11) involving the juxtaposition 
of Abl1 of chromosome 9 with a part of Bcr on chromosome 22.21 The fusion protein 
product BCR-Abl, is a kinase that is constitutively activated, leading to uncontrolled cell 
growth and proliferation.21-23  
In 2001, the BCR-Abl tyrosine kinase inhibitor Imatinib, was approved for the 
treatment of CML and a 5-year follow-up displayed a remarkable increase in the overall 
survival rate from 50% (following cytotoxic chemotherapy) to 89%.24 The success of 
Imatinib in converting an invariably fatal disease into a chronic, manageable condition 
spurred great interest in developing inhibitors of other kinases believed to be involved in a 
variety of cancers.25 Most such efforts have been directed toward the development of 
inhibitors of receptor tyrosine kinases upstream of Ras (EGFR, Her2) and non-receptor 
kinases downstream from it (BRaf, Mek1/2, and Erk1/2). Several of these drugs are 
currently in clinical trials while others have been approved for the treatment of certain 
cancers. 
Few kinase inhibitors, however, have shown the dramatic efficacy and safety 
observed with Imatinib therapy. This is a consequence of the fact that, unlike CML, the 
majority of tumor types are not ‘addicted’ to a single oncogenic kinase for growth.25 This 
does not suggest, however, that kinase inhibitors can only be used to treat ‘addicted’ 
cancers. The model for the Ras-signaling pathway presented above is a gross 
oversimplification of the complex signaling that occurs in cell growth and proliferation. 
This complexity is multiplied by the incredible degree of crosstalk that occurs between 
pathways, which gives rise to multiple redundant pathways. A second complication that 
arises in the use of kinase inhibitors is that the off-target inhibition of certain kinases can 
lead to life-threatening toxic effects and fatalities. Consequently, success in treating 
malignancies not dependent on a single kinase will depend on targeting multiple, yet 
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specific, kinases while sparing those that can lead to toxicity. Identifying the appropriate 
kinases to be targeted in specific cancers remains one of the biggest challenges today, and 
the development of selective compounds or ‘probes’ will be necessary to delineate the 
functional role of individual kinases.  Chapter IV details our efforts in developing covalent 
inhibitors for underexplored sites of a kinase that could provide uniquely selective 
compounds for probing the roles of closely related kinases. 
A third cause of the failure of kinase inhibitors in the treatment of certain cancers 
is the development of resistance to treatment. Such resistance is commonly observed in 
patients receiving Imatinib therapy and renders the drug ineffective. Chapter II details our 
efforts in developing a highly selective Bcr-Abl inhibitor that is capable of inhibiting one 
of the most common mutations observed in CML. However, as targeted therapy with kinase 
inhibitors is not a cure for cancer, but rather the conversion to a chronic disease, the 
problem of resistance is likely to grow in the coming years as the overall survival rate of 
patients continues to increase. Consequently, the exploration of other viable targets is 
essential for improvements in targeted therapy. Chapter III details our efforts in 
developing inhibitors for one such target, Grb2, which in addition to being a key 
component of Ras-signaling, is also known to play a role in CML.  
1.6. Conclusions 
Despite the fact that our current abilities for the treatment of certain cancers seemed 
unattainable until only a decade ago, advancements in targeted therapy have not kept up 
with growing incidences of cancer. While kinase inhibitors have been the most successful 
forms of targeted cancer chemotherapy, a comprehensive understanding of the biological 
roles of individual kinases will be necessary for therapies to be effective in a majority of 
cancers. The development of selective kinase probes and inhibitors, is, therefore, essential, 
for continued improvement in cancer chemotherapy. For therapies that are currently 
effective against certain types of cancer, the development of resistance poses a grave risk. 
Consequently, in addition to developing next-generation inhibitors that can overcome such 
resistance, the identification and exploration of non-kinase targets will be vital.  
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CHAPTER II 
Development of a Selective Inhibitor of Abl Kinase that Targets the T315I 
Gatekeeper Mutation 
2.1. Abstract 
 Patients with Chronic Myelogenous Leukemia (CML) show a dramatic 
improvement in 5-year overall survival on treatment with the Bcr-Abl inhibitor, Imatinib. 
Long term treatment, however, invariably leads to the development of point mutations in 
the c-Abl kinase domain resulting in Imatinib being rendered ineffective. Second 
generation inhibitors are effective against all but the single most common point mutation, 
the T315I ‘gatekeeper’ mutation. While the third generation inhibitor, Ponatinib, can 
inhibit the gatekeeper mutant c-Abl, it displays severe and life-threatening toxicity possibly 
due to its promiscuity in inhibiting other kinases. This chapter details our efforts in 
developing a selective inhibitor of c-Abl with the ability to inhibit the clinically relevant 
T315I mutant. Based on the prevailing model of selectivity for the c-Abl kinase domain, 
we developed a library of small molecules targeting the c-Abl kinase domain and identified 
compound 2.4 with high potency for both the wild type (380 pM) and T315I (550 pM) Abl. 
The potency was comparable to that of Ponatinib, with a significantly improved spectrum 
of selectivity. The efficacy of compound 2.4 was demonstrated both biochemically and in 
cellulo in wild type and T315I Bcr-Abl dependent cell lines. Additionally, the development 
of compound 2.4 led to a more comprehensive understanding of pharmacophores necessary 
for targeting certain groups of kinases while sparing others.  
2.2. Chronic Myelogenous Leukemia and Treatment with Imatinib 
A striking example of a cancer caused by a genetic abnormality through 
chromosomal translocation is that of Chronic Myelogenous Leukemia (CML). The 
reciprocal translocation t(9;22)(q34;q11) involves juxtaposition of Abl1 of chromosome 9 
with a part of Bcr on chromosome 22 giving rise to a shortened chromosome 22, termed 
the Philadelphia chromosome.1 The two possible fusion protein products, p185, and p210 
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BCR-Abl have deregulated tyrosine kinase activity leading to uncontrolled cell growth and 
proliferation.1-3 The p210 form of BCR-Abl is observed in over 95% of patients with CML 
and 20% of patients with acute lymphocytic leukemia (ALL), while the p185 form is seen 
in 10% of patients with ALL.4  
CML accounts for about 15% of leukemias in adults and left untreated, is 
characterized by three distinct clinical phases. The first, a chronic phase lasting three to six 
years, followed by an accelerated phase lasting 1 to 1.5 years, and finally a blast crisis 
resulting in the patient’s death within 3 to 6 months.5-7 Prior to 2001, treatment options for 
patient with CML were limited to conventional chemotherapy, allogeneic stem cell 
transplantation (for the 20% of patients that were eligible), and interferon-α therapy 
resulting in a 5-year overall survival rate of 50% when treated in the chronic phase.7 In 
2001, the c-Abl tyrosine kinase inhibitor Imatinib, was approved for treatment of CML and 
a 5-year follow-up displayed a remarkable increase in overall survival rate to 89%.8 
Patients in the accelerated phase receiving Imatinib, however, demonstrated a significantly 
lower estimated 4-year survival rate of 53%.9 Furthermore, long-term treatment often gave 
rise to Imatinib-resistant CML, necessitating the development of next generation inhibitors.  
2.3. c-Abl and its Conformations 
c-Abl is a 150 kDa protein, the N-terminal consisting of the SH2, SH3 and kinase 
domains, and a 90 kDa C-terminal half is unique and consists of DNA binding domains 
and repeating actin binding domains.10 Two isoforms of c-Abl have been identified, one of 
which is myristoylated at the N-terminus (c-Abl 1a), and the other which is 19 residues 
shorter and non-myristoylated (c-Abl 1b). Amino acid numbering throughout this chapter 
is based on the 1b isoform. The minimal domains required for tyrosine kinase activity and 
regulation comprise residues 1 to 531 and include the SH3 domain, SH2 domain, and the 
catalytic kinase domain.11  
The catalytic domain has a typical kinase fold12, comprised of an N-lobe, which is 
primarily made up of β-sheets and a C-lobe, which is mostly made up of α-helices. A deep 
hydrophobic cleft exists between the two lobes forming the ATP-binding site. Key 
structural elements illustrated in Figure 2.1 required for binding to ATP and catalysis 
include: 
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i. A hinge region in the cleft between the lobes forms hydrogen bonds with ATP and 
most small molecule inhibitors. 
ii. A phosphate-binding loop (P-loop) forms the ceiling of the ATP binding site and 
clamps down on the phosphates of ATP, enabling catalysis. The glycine-rich nature 
of the P-loop enables flexibility in the absence of ATP, resulting in different 
conformations in different kinases.13 
Figure 2.1. Key structural features of the kinase domain of c-Abl (PDB 2GQG).  A loop between 
the N- and C-terminal lobes is termed as the hinge region (shown in yellow) and is preceded by the 
gatekeeper Thr315 residue. A flexible glycine rich P-loop (red) positions ATP for catalysis. An 
activation loop (green) is responsible for regulation and begins with a DFG motif. Asp381 (of DFG) 
is positioned in close proximity to Lys271 and Glu286 that collectively form a conserved triad 
responsible for catalysis (orange).  
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iii. An activation loop, containing a conserved DFG-motif (residues 381-383) and a 
tyrosine (Y393) that serves as a phosphorylation site, plays a role in regulating the 
enzyme.13 
iv. Conserved residues involved in catalysis are Lys271, Asp381 of the DFG motif, 
and Glu286 on the αC helix. 
v. An important residue determining access to a back-pocket of the kinase is Thr315 
and is also termed the ‘gatekeeper’ residue. 
c-Abl binds to ATP-competitive small molecules in three distinct conformations. 
The first, an active ‘DFG-in’ conformation, mimics the binding mode of ATP, in which 
Phe382 of the DFG-motif is buried in a hydrophobic pocket, positioning Asp381 for 
catalysis (Figure 2.2, left). Inhibitors that bind to this conformation are known as type-I 
inhibitors and are restricted to contacts with the hinge region. The second, an inactive 
‘DFG-out’ conformation, has a substantial movement of the activation loop, in which 
Phe382 is flipped outward creating a hydrophobic cavity that can be occupied by (type-II) 
inhibitors extending from the hinge region (Figure 2.2, right). The third, ‘αC-out’ 
conformation, is also inactive and is caused by the outward movement and rotation of the 
αC-helix, preventing the optimal positioning of Glu286 for catalysis. The αC-out 
conformation will not be discussed further in this chapter. 
Figure 2.2. Active and inactive conformations of c-Abl. Left – Active DFG-in conformation with 
Lys271, Asp381, and Glu286 (orange) positioned for catalysis (PDB 2GQG). Right – Inactive DFG-
out conformation with Phe382 (yellow) flipped outward creating a new hydrophobic cavity (PDB 
1IEP). 
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The remarkable efficacy and selectivity of Imatinib was initially attributed to its 
ability to bind to c-Abl in a DFG-out conformation. This conformation was then believed 
to be accessible by only a few kinases and not by others, notably c-Src, that shares 46% 
sequence identity with c-Abl.14-15  This was subsequently proved to be untrue as a crystal 
structure of c-Src bound to Imatinib, displayed an identical DFG-out conformation.16 A 
detailed look at the basis for selectivity toward c-Abl is described in Section 2.6. The 
Imatinib/c-Abl crystal structure (Figure 2.3, Left) showed the pyridine and pyrimidine 
rings positioned in the ATP binding pocket, with the pyridine nitrogen making an H-bond 
with the backbone of Met318 in the hinge region. The P-loop of c-Abl forms a hydrophobic 
cage around the pyridine and pyrimidine ring systems. The compound extends past the 
gatekeeper residue Thr315 through an ortho-substituted aniline linker and makes an H-
bond with its side chain. Four additional hydrogen bonds are formed between the 
compound and residues Glu286, Asp381, His361, and Ile360. A majority of contacts are 
mediated by van der Waals interactions with a total of 1251 Å2 surface area buried between 
Imatinib and c-Abl. 14  
2.4. Imatinib-Resistant CML and Second Generation Inhibitors 
Patients display either an innate resistance or an acquired resistance to Imatinib on 
prolonged treatment. To date, over 50 point mutations in the kinase domain of c-Abl have 
been observed that reduce or abrogate binding to Imatinib while retaining catalytic activity. 
Mutations that render Imatinib ineffective can be of several types - those that possibly 
prevent kinking of the P-loop, those that sterically occlude small molecules, and those that 
Figure 2.3. Binding conformation of Imatinib to c-Abl. Left – Imatinib forms H-bonds with the hinge, 
Thr315, and 4 additional residues on extending past the gatekeeper. Right – The T315I mutation leads 
to loss of an H-bond and steric occlusion of Imatinib.  
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de-stabilize the DFG-out conformation.17 Despite the large number of mutations observed, 
several of these are relatively rare. A handful of residues; Gly250, Tyr253, Glu255, 
Thr315, Met351, and Phe359, account for about 70% of all mutated residues.18 An 
additional complication involves the fact that two of the more commonly detected 
mutations, Y253F, and E255K, have a greater oncogenic potential than the native enzyme 
itself. Consequently, though Imatinib binding to these mutants is reduced by only 5 to 10-
fold in biochemical studies19, inhibition of cellular proliferation is disproportionately 
affected.18 Most mutations are observed in the P-loop of c-Abl, which can accommodate 
amino acid substitutions without losing catalytic activity, owing to its dynamic nature. The 
single most common mutation, however, is the T315I gatekeeper mutation20 which 
completely eliminates binding to Imatinib (Figure 2.3, Right), due to steric hindrance of 
Figure 2.4. FDA-approved drugs for the treatment of CML and the RET inhibitor AST-487. Red 
indicates the portion of the molecule binding to the ATP-binding pocket and makes contacts with the 
hinge region. Black indicates the portion directly adjacent to the gatekeeper residue and is referred to 
as the linker group. Blue indicates the portion of type II inhibitors that binds to the cavity created by 
the outward flip of the DFG motif. Green in Dasatinib and Bosutinib is primarily a solubilizing group. 
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the bulkier Isoleucine substitution, loss of an H-bond with the side chain of Threonine, and 
an increased affinity for ATP.  
Point mutations leading to Imatinib-resistant CML necessitated the development of 
second generation inhibitors that could overcome this resistance. Nilotinib, Bosutinib, and 
Dasatinib are effective at inhibiting most P-loop mutants of c-Abl. The inhibitors are, 
however, completely ineffective at inhibiting the T315I mutation, possibly due to the same 
mechanisms as observed for Imatinib. 
2.5. Ponatinib and c-Abl Inhibitors that Target the T315I Gatekeeper Mutation 
All first and second generation inhibitors approved for the treatment of CML form 
a critical H-bond with the side-chain hydroxyl group of Thr315. Mutation of this residue 
to Ile315 prevents high-affinity binding, requires a significant rearrangement of the binding 
conformation and alters the topology of the binding pocket.21-22 
Three general design elements have now been identified for the development of 
type II inhibitors that can bypass the gatekeeper mutant c-Abl (Figure 2.5). The first, 
identified empirically, involves incorporating additional H-bond donor and acceptor atoms 
to increase the number of polar interactions with the hinge region.  Consequently, binding 
is not entirely reliant on the single H-bond formed between the linker aniline and the side 
chain of Thr315, and a mutation to Ile315 does not significantly reduce affinity. Molecules 
incorporating this design element, are, however, very potent inhibitors of Src Family 
Figure 2.5. Design elements for circumventing the T315I mutation. Additional H-bond donor and 
acceptor atoms in the hinge-binding portion of the molecule, compensates for the loss of an H-bond 
with the side chain of Thr315. Additionally, a slight rotation of the ortho-aniline linker prevents a 
clash with the bulky isoleucine residue (Left). An alkyne linker (Middle) and a para-substituted 
phenol (Right) are not sterically occluded by a bulky gatekeeper and are not reliant on an H-bond. 
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Kinases (SFKs) and have poor kinome-wide selectivity.22-23 A possible reason for the 
promiscuity of these compounds is discussed in Section 2.6. 
The second strategy involves the use of an alkyne to link the hinge-binding portion 
of the molecule to the type-II tail. Unlike the larger, ortho-substituted aniline linker present 
in Imatinib and all second generation c-Abl inhibitors, the compact alkyne linker is neither 
sterically occluded nor reliant on the ability to form an H-bond with the gatekeeper residue. 
Since then, a number of alkyne and alkene linker-based compounds have been identified 
to inhibit both wild-type and T315I c-Abl.21, 24-25 None of these compounds, however, 
display a spectrum of selectivity similar to Imatinib or Nilotinib. Further development of 
this class of compounds by ARIAD Pharmaceuticals, led to the approval of Ponatinib for 
the treatment of Imatinib resistant and refractory CML. In addition to inhibiting wild-type 
and T315I c-Abl, Ponatinib inhibited almost every other clinically relevant mutant with 
high potency.21 Ponatinib’s approval was through the FDA’s Accelerated Approval 
pathway, based on data from a single phase II trial of 449 patients, 29% of which harbored 
a T315I mutation.26  A consequence of a short follow-up period of 10 months was that 
primary endpoints were surrogate outcomes such as hematological and cytogenetic 
response, and not outcomes such as mortality. At the time of approval, 56% of patients 
with chronic-phase CML showed a major cytogenetic response, and that number climbed 
to 70% when only considering patients with a T315I mutation.27 10 months after approval, 
however, the FDA temporarily suspended sales of Ponatinib due to mounting evidence of 
serious and life-threatening toxicity after a longer follow-up period. 24% of participants 
from the Phase II study experienced myocardial infarction, stroke, limb ischemia, and 
stenosis of blood vessels.  Similarly, a 30-month follow-up of participants from the Phase 
I study demonstrated vascular events in 48% of patients.26 Subsequently, the suspension of 
sales was partially lifted and a black-box warning was issued for the use of Ponatinib, while 
a larger Phase III trial for approval as a first-line therapy was halted. Though the exact 
cause of its toxicity has not been determined, it is hypothesized that it may be due to its 
high promiscuity in potently inhibiting multiple kinases and/or due to an effect related to 
its scaffold. The kinases involved have not been unambiguously identified, however, 
evidence suggests that the inhibition of kinases critical for angiogenesis such as VEGFR-
1 (FLT1), VEGFR-2 (KDR), and VEGFR-3 (FLT4) could cause cardiotoxicity.28 Other 
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important targets that may be involved in cardiotoxicity include HER2, c-KIT, PDGFRα/β, 
and JAK2.29 With the exception of HER2, Ponatinib inhibits all of the above-listed kinases 
very potently.30  
The last design element for developing T315I c-Abl inhibitors includes a para-
substituted phenol or aniline linker.  Such a linker does not make an H-bond with the 
gatekeeper residue and effectively bypasses the Ile315 mutant. This class contains 
compounds such as DCC-203631, AST-48732 (Figure 2.4), and Sorafenib33, which can 
inhibit both wild-type and T315I c-Abl, but are currently under clinical investigation for 
cancers other than CML. AST-487 and Sorafenib are extremely promiscuous pan-kinase 
inhibitors. DCC-2036, though slightly more selective, inhibits a number of unwanted 
targets including the SFKs. Incorporation of these design elements into the development 
of a selective inhibitor of wild-type and T315I c-Abl has been described in Section 2.7. 
2.6. Selectivity for c-Abl over c-Src 
 Though c-Abl and c-Src do not belong to the same family of kinases, their kinase 
domains are highly conserved and share 46% sequence identity. With a few exceptions, 
most inhibitors of c-Abl also inhibit c-Src potently. As a result, c-Src has been used as an 
initial selectivity filter to screen for compounds that could potentially have a favorable 
spectrum of selectivity. Imatinib is the most striking such exception, with over 3000-fold 
difference in selectivity for c-Abl over c-Src. The aforementioned X-ray crystal structure 
of c-Src bound to Imatinib irrefutably proved that it too could adopt a DFG-out 
conformation.16 The low affinity of Imatinib for c-Src was especially puzzling given that 
the crystal structure revealed it made almost identical contacts to those seen in the 
Imatinib/c-Abl complex. It was hypothesized that both enzymes must be in an equilibrium 
between the DFG-in and DFG-out conformations and differed in the probability of 
occupying a particular conformation. Such a conformation-selection mechanism involved 
c-Src overcoming a steep entropic penalty to adopt a DFG-out conformation as compared 
to c-Abl where this conformation was more readily available.16, 34-36  
This hypothesis too was weakened when analogs of Imatinib with a hydrophilic 
hinge-binding head group were shown to be equipotent for c-Src and c-Abl.23 The P-loop 
of c-Src is extended while that of c-Abl is kinked and forms a hydrophobic shell around 
Imatinib (Figure 2.6, top). Seeliger et al. hypothesized that Imatinib’s selectivity for c-Abl 
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over c-Src could be attributed to the kinked P-loop of c-Abl that makes hydrophobic 
contacts with the pyridine and pyrimidine rings of Imatinib.23 The extended P-loop of c-
Src offered no such protection from solvent molecules, thus increasing the solvation 
penalty on binding. Altering Imatinib’s hinge binding region to a more polar hydrophilic 
surface enabled favorable binding to c-Src. Furthermore, it was suggested that Imatinib’s 
sensitivity to P-loop mutants in c-Abl could be explained if such mutants prevented kinking 
of the P-loop, thus exposing Imatinib to solvent.23, 37 Recent kinetic evidence has confirmed 
that c-Src does not pay a significant energetic penalty for conformation selection. Instead, 
it has been suggested that Imatinib binds to the kinases via a two-step mechanism (Figure 
2.6, bottom). The first, involves Imatinib binding to the DFG-out conformation of both c-
Src and c-Abl, followed by an induced-fit step that is significantly slower in c-Src as 
compared to c-Abl.38-39 Though the nature of the intermediate conformation is unknown, it 
has been proposed that it may involve an extended P-loop that kinks readily in the case of 
c-Abl allowing for favorable binding to Imatinib. In the case of c-Src, kinking of the P-
loop would be significantly slower accounting for the unfavorable binding to Imatinib.39 
While being a compelling argument, certain problems lie with the P-loop 
hypothesis. Lck, a Src Family Kinase (SFK) with an extended P-loop, is a potent target of 
Figure 2.6. Determining the selectivity of Imatinib for c-Abl over c-Src. Top left – The kinked P-
loop of c-Abl forms a hydrophobic shell around Imatinib (PDB 1IEP). Top Right – X-ray crystal 
structure of Imatinib/c-Src complex with an extended P-loop. Bottom – A two-step mechanism 
involving a slow induced fit step. 
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Imatinib.19 If selectivity between c-Abl and the SFKs were solely determined by kinking 
of the P-loop, the potency of Imatinib for Lck should have been substantially reduced. 
Furthermore, Nilotinib, which bears a hinge-binding head group identical to Imatinib, does 
not show significant sensitivity to P-loop mutants.19, 40 Despite these flaws, the P-loop 
hypothesis does at least partially explain selectivity of Imatinib for c-Abl over c-Src and 
was the basis for our design of selective inhibitors for c-Abl that could target the T315I 
gatekeeper mutation.  
2.7. Development of Selective Inhibitors Bypassing the Gatekeeper Mutation  
Inhibitors that have been successful in bypassing the gatekeeper mutation mostly bind 
c-Abl in a DFG-out conformation. A general strategy for the development of inhibitors that 
can reliably bind to a given kinase in a DFG-out conformation has been well-established.41 
Necessary moieties include a hinge-binding motif, a hydrophobic linker that binds adjacent 
to the gatekeeper residue, an amide or urea that can H-bond to the conserved catalytic 
Asp381 and Glu286 residues, and finally a second hydrophobic moiety that binds to a 
pocket created by the outward flip of Phe382.  
Based on the ability of the non-selective inhibitors, DCC-2036 and AST-487, to inhibit 
the T315I mutant, we employed a para-substituted aminophenol linker to bypass the bulky 
isoleucine gatekeeper (see Section 2.5). Based on the above-mentioned selectivity 
hypothesis (Section 2.6), we reasoned that a hydrophobic hinge-binding moiety could 
potentially offer selectivity for c-Abl over c-Src. To test this hypothesis, we were interested 
in: 
a. Altering the hinge-binding motif 
b. Altering the type-II tail  
 
a. Altering the hinge-binding motif 
The compound AST-487 (Figure 2.4), is a promiscuous kinase inhibitor that binds to 
the DFG-out conformation of the kinase. Despite its promiscuity, it has the advantage of 
being a very potent inhibitor of c-Abl (Kd = 680 pM) and the ability to inhibit clinically 
relevant c-Abl mutants including the T315I gatekeeper mutant with high potency (Kd = 2.8 
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nM).19 We hypothesized that replacing the head group of AST-487 with hydrophobic 
moieties could potentially increase selectivity for c-Abl over c-Src and associated SFKs 
while retaining potency.  
Replacing the 6-aminopyrimidine ring of AST-487 with a slightly more hydrophobic 
pyridine ring in compound 2.1 and a pyridine carboxamide in compound 2.2 retained 
potency for c-Abl while providing moderate selectivity over c-Src (see Table 2.1). 
Gratifyingly, in line with our hypothesis, compound 2.3 with a very hydrophobic naphthyl 
ring entirely lacking a H-bond acceptor atom, displayed a Ki of 155 nM for c-Abl with a 
dramatic loss in potency for c-Src with no inhibition below 27 µM (the highest 
concentration of compound tested). Moreover, the pyridine containing compounds (2.1 and 
2.2) as well as the naphthyl-containing compound 2.3, maintained potency for T315I c-
Abl. While useful in proving that a hydrophobic motif could provide for a dramatic increase 
Table 2.1. Ki values of compounds with an altered hinge-binding motif.  
Ki < 1 nM indicates the compound was too potent to characterize in our assay. Compound 2.4 was characterized in a binding 
assay and displayed a Kd of 380 pM for wild-type c-Abl and 550 pM for T315I c-Abl. 
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in potency for c-Abl over c-Src, compound 2.3 has the drawbacks of significantly lower 
potency for wild-type c-Abl and sensitivity towards P-loop mutants of c-Abl, such as the 
Y253F mutant, which showed no inhibition below 9 µM. It did suggest, however, that a 
balance between a hydrophilic and a very hydrophobic hinge-binding moiety could provide 
for selectivity over c-Abl over c-Src while maintaining potency and retaining the ability to 
inhibit P-loop mutants of c-Abl. Consequently, we switched to hydrophobic rings that 
contained at least one H-bond acceptor atom.  
 Compounds 2.4 – 2.6 included region-isomers of quinoline ethers and amines, and 
each of these compounds retained high potency for c-Abl, with compound 2.4 being the 
most potent. Compound 2.4 was too potent to characterize in our assay (see Experimental 
for details). Instead, Kd determination of compound 2.4 through a binding assay, revealed 
it potently inhibited both wild-type c-Abl (380 pM) and T315I c-Abl (550 pM). Its strong 
inhibition of Y253F c-Abl and 570-fold loss in potency for c-Src (Ki = 216 nM), made it 
an excellent lead compound.  Unexpectedly, compounds 2.5 and 2.6 showed an even more 
dramatic loss of potency for c-Src, with Ki values of 12 µM and 4.5 µM, respectively. The 
5-6 fold loss in potency for wild type c-Abl and sensitivity for the T315I and Y253F 
mutants precluded the further development of these compounds. Despite an equal number 
of H-bond donor atoms and overall hydrophobicity as 2.4, the startling loss in potency 
against c-Src for compounds 2.5 and 2.6 suggests that desolvation due to kinking of the P-
loop is not the sole determinant of selectivity for c-Abl over c-Src. 
b. Altering the type-II tail 
With the hinge-binding group in 2.4 providing an adequate balance between potency 
for c-Abl and selectivity against c-Src, the type-II tail was modified to probe whether either 
of these attributes could be accentuated (Table 2.2) 
While removal of the N-methyl piperazine ring in compound 2.7 maintained both 
potency and selectivity, its poor solubility and pharmacokinetic properties precluded its 
further use. Removal of the trifluoromethyl group that occupies the hydrophobic pocket 
created by the outward flip of Phe382 in compound 2.8 led to a substantial loss in potency 
for c-Abl. Finally, other work in our lab has suggested that a meta-tolyl pyrazole containing 
type-II tail shows an enhancement in kinome-wide selectivity as compared to 
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trifluoromethylphenylpiperazine tail. Incorporation of the meta-tolyl pyrazole tail in 
compound 3.8, however, led to a 20-fold loss in potency for c-Abl while maintaining 
potency for c-Src. Consequently, the original compound 3.4 was selected for further 
investigation. 
 
2.8. Kinome Profiling of Compound 2.4 
While potency for c-Src over c-Abl served as a useful initial selectivity filter, 
kinome-wide profiling was necessary to assess the actual selectivity of compound 2.4. A 
concentration of 40 nM (100-fold greater than the Kd of the primary target, c-Abl) was used 
in a primary screen performed through the KINOMEscan™ profiling service of the 
DiscoveRx Corporation. Kinases, probes immobilized on affinity resin, and compound 2.4 
were incubated at room temperature for 1 hour, and the percentage of probe remaining 
bound to the kinase was measured (see Experimental for details). Thus, the selectivity of 
compound 2.4 was assessed for 395 non-mutant protein kinases and 61 mutants and 
atypical kinases.  
Table 2.2. Ki values of compounds with an altered type-II tail 
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Compound 2.4 displayed an S(35) selectivity score of 0.084 and an S(10) selectivity 
score of 0.035. The S(35) score indicates that 8.4% of non-mutant kinases had less than 
35% of the probe remaining (Figure 2.7). Likewise, the S(10) score indicates that 3.5% of 
non-mutant kinases had less than 10% of the probe remaining. Additionally, compound 2.4 
inhibited all relevant clinical mutations of c-Abl potently.   
A direct comparison to drugs approved for the treatment of CML is not possible 
since published data includes either primary screens at a single concentration of 10 µM 
(several-fold higher than the Kd of the intended target) or individual Kd values for each of 
Figure 2.7. Selectivity profile of compound 2.4. The kinome is represented as a phylogenetic 
tree with each green dot representing an individual kinase. Red spots indicate interactions with 
compound 2.4, and the larger the spot, the stronger is the interaction. 
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the 395 non-mutant kinases. However, some general conclusions can be drawn from 
comparing the selectivity profile of compound 2.4 to the profiles of approved drugs.  
For a valid comparison, it is important to identify the selectivity score that best reflects the 
kinases inhibited at or below the screening concentration. It is important to note that the 
percentage of probe remaining is not a direct measure of the Kd of a small molecule for a 
particular kinase. For example, compound 2.4, screened at a concentration of 40 nM shows 
54% of probe remains bound to the kinase SIK2; this, however, does not mean that the Kd 
of compound 2.4 for SIK2 is 40 nM. Instead, a comparison of the primary screen scores 
versus the Kd of small molecules by KINOMEscan™ reveals that a 10% cut-off is more 
typically reflective of targets with a Kd at or below the screening concentration (For details, 
see Section 2.11 – Correlating Selectivity Scores to Kd values). 
 Applying a cut-off of 10%, compound 2.4 inhibited 14 kinases with a Kd value 
likely below 40 nM. In comparison, Imatinib inhibits only 9 kinases with a Kd values within 
100-fold of its intended target (c-Abl). This isn’t surprising, considering Imatinib happens 
to be the second most selective kinase inhibitor that has been approved by the FDA. The 
selectivity of compound 2.4, however, is comparable to that of Nilotinib which inhibits 13 
kinases potently, and far surpasses the selectivity of Dasatinib, Bosutinib, and AST-487 
which inhibit 30, 28, and 56 kinases, respectively.  These analyses, though not exact, offer 
a qualitative representation of the selectivity spectrum of compound 2.4 in comparison to 
other clinical candidates.  
Two general trends emerge in terms of the pharmacophores responsible for 
targeting certain groups of kinases. A comparison of the targets of compound 2.4 and AST-
487 reveals every target of compound 2.4 to be a potent target of AST-487. The opposite, 
however, is not true. AST-487, which has an identical linker moiety and type-II tail as 
compound 2.4, is highly promiscuous indicating that the selectivity of compound 2.4 is 
entirely derived from its hydrophobic hinge-binding moiety. The hydrophobic quinoline of 
compound 2.4 was initially used to provide for selectivity for c-Abl over c-Src and other 
SFKs. However, it seems to have provided for selectivity over at least 30 other targets of 
AST-487 listed in Table 2.3. 
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 All kinases inhibited by Imatinib are also inhibited by compound 2.4, suggesting 
that these kinases may have a better affinity for type-II inhibitors. An analysis of the targets 
of 2.4 not inhibited by Imatinib, reveals an interesting fact. Of the 23 kinases that are at 
least weak affinity targets of 2.4, but not of Imatinib, 19 have a bulky gatekeeper reside in 
the form of phenylalanine, isoleucine, valine, methionine, or leucine (Table 2.4). The 
exceptions, Zak, EphA8, Blk, and p38α have the same threonine gatekeeper residue as c-
Abl. This suggests that the stark selectivity of Imatinib is at least in part due to the inability 
to bind to kinases with bulky gatekeeper residues. Consequently, the advantage of 
compound 2.4 in being able to bypass the gatekeeper residue is also a shortcoming in terms 
of kinome-wide selectivity. In fact, most of these additional targets are shared by other 
inhibitors of c-Abl that can inhibit the T315I mutant such as AST-487, DCC-2036, and 
Sorafenib. This underscores the difficulty in developing selective inhibitors that can also 
Table 2.3. 56 kinases inhibited by AST-487 with a Kd < 69 nM. % Control indicates the 
percentage of probe that remains bound to each kinase after incubation with 40 nM compound 
2.4. High affinity targets of 2.4 are highlighted in red, medium affinity in orange, and those in 
green have little to no affinity.  
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inhibit clinically relevant kinase mutants as these mutants might share certain 
commonalities with off-targets.  
 
Lastly, Ponatinib has not been profiled using the same assay platform as compound 
2.4. IC50 values of Ponatinib, however, have been obtained for a panel of 82 kinases. Its 
IC50 against c-Abl was found to be 370 pM, and if a cutoff of 37 nM is used, Ponatinib was 
found to inhibit 43 of the 82 kinases (52%) in the panel.21 Evaluating the same kinases 
from within the KINOMEscreen™ profile of compound 2.4, revealed it to inhibit only 9 
of the 82 kinases (11%) on using a percent control cutoff of 10% and 18 kinases (22%) on 
using a percent control cutoff of 35%. In addition to all nine SFKs, which Ponatinib 
inhibited potently, its additional off-targets included the receptor tyrosine kinases EphA2-
8, EphB1-3, FGFR1-4, and VEGFR1-3. Compound 2.4 was found to be significantly more 
selective and does not inhibit some of the off-targets that could be related to the 
cardiotoxicity observed with Ponatinib.  
2.9. In Cellulo Results 
The efficacy of compound 2.4 was evaluated in a number of non-CML and CML 
related cell lines by Taylor Johnson (Table 2.5). Ba/F3 cell line is an immortalized murine 
bone marrow-derived pro-B-cell line which when transformed with Bcr-Abl becomes 
entirely dependent on it. Compound 2.4 potently inhibited the growth of both wild-type 
Table 2.4. Targets of 2.4, but not of Imatinib. Only 4 of the 23 targets have a threonine 
gatekeeper residue (highlighted in red). 
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and T315I forms of Bcr-Abl transformed Ba/F3 cells. Imatinib demonstrated comparable 
growth inhibition in wild-type Bcr-Abl transformed Ba/F3 cells but showed no inhibition 
in those transformed with the gatekeeper mutant. Ba/F3 cells, while very useful in 
determining the effect of inhibiting a particular kinase in its native state, does not accurately 
reflect the complexity of inhibiting Bcr-Abl in CML.  
Consequently, BV-173, a cell line derived from a patient with Ph+ Acute 
Lymphocytic Leukemia, and K562 cells, obtained from a CML patient in blast crisis were 
used. Both cell lines were potently inhibited by compound 2.4 with low nanomolar growth 
inhibition values.  
Compound 2.4 displayed a GI50 value of 6 nM and 144 nM against the Imatinib-
resistant cell lines, BV-173R and K562R respectively. The BV-173R cell line is 
predominantly dependent on T315I Bcr-Abl and is thus effectively inhibited by compound 
2.4. The K562R cell line, however, is not dependent on Bcr-Abl mutants, but instead 
overexpresses the Src Family Kinase, Lyn. Compound 2.4 does not inhibit Lyn potently 
and consequently shows lower potency in K562R cells. Any attempt at developing an 
inhibitor that would also potently inhibit Lyn, would likely increase its spectrum of targets 
and could lead to toxicity. This underscores the importance of combination therapy in the 
treatment of cancer since mutation of the intended target is not the sole cause of resistance.   
Lastly, Ba/F3 parental cells and human mammary epithelial (HME) cells were used 
as representatives of healthy cells. Compound 2.4 did not significantly inhibit either cell 
line demonstrating a large therapeutic window in the inhibition of cancer cells versus 
healthy cells.  
Table 2.5. In cellulo evaluation of compound 2.4. 
27 
 
2.10. Conclusions 
The discovery of Imatinib has heralded a new age in the treatment of CML 
Leukemia and spurred the investigation of kinase inhibitors for the treatment of several 
other cancers. Over the last two decades, the identification of entire human kinome and 
advancements in profiling technology have brought about a deeper understanding of the 
complexity and challenges involved in developing selective inhibitors of a particular 
protein kinase. Imatinib’s success is even more apparent now as it remains the mainstay of 
CML therapy 15 years after its approval. Despite its development at a time when the entire 
kinome had not been identified, it remains one of the most selective kinase inhibitors 
approved to date. It is, however, ineffective in a subset of patients with CML who have an 
innate or acquired form of resistance to Imatinib.  
Attempts at overcoming Imatinib resistance have led to the development of second 
and third-generation inhibitors. While second generation inhibitors are effective in treating 
several forms of Imatinib-resistant CML, they are incapable of treating resistance arising 
from the T315I gatekeeper mutation of Bcr-Abl.  
The third generation inhibitor, Ponatinib, can overcome this resistance but has life-
threatening toxic effects in a large percentage of patients thereby severely limiting its use. 
The toxicity of Ponatinib has been attributed to the fact that it inhibits several off-target 
kinases in addition to Bcr-Abl, some of which might be responsible for its cardiotoxic 
effects.  
Consequently, this chapter detailed our efforts in developing a selective c-Abl 
inhibitor that is capable of inhibiting the T315I mutant form of the enzyme. Utilizing a 
pharmacophore that can inhibit T315I Abl, we developed a library of small molecules 
based on a hypothesis of obtaining selectivity for c-Abl over c-Src. Our lead molecule, 
compound 2.4, inhibited c-Abl and mutant forms of c-Abl very potently while displaying 
a 570-fold lower potency for the homologous enzyme c-Src. Kinome profiling of the 
compound 2.4 demonstrated it to be one of the most selective inhibitors of c-Abl, with a 
spectrum of selectivity similar to Nilotinib and narrower than that of other drugs used in 
the treatment of CML. The biochemical potency of 2.4 translated to effective inhibition of 
CML cell lines while its narrow spectrum of selectivity provided for a large therapeutic 
window using a toxicity model of HME cells.  
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2.11. Materials and Methods 
General Synthetic Methods 
Unless otherwise noted, all reagents were obtained via commercial sources and 
used without further purification. Tetrahydrofuran (THF) and dichloromethane (CH2Cl2) 
were dried over alumina under a nitrogen atmosphere. 1H and 13C NMR spectra were 
measured with a Varian MR400, Varian VNMRS 500, or Inova 500 spectrometer. Mass 
Spectrometry (HRMS) was carried out by the University of Michigan Mass Spectrometry 
Facility (J. Windak, director). 
Synthetic Protocols 
 
Synthesis of 2.10 – Compound 2.10 was synthesized according to a previously described 
procedure.  
 
Scheme 2.1. Synthesis of compounds 2.1 – 2.6. 
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Synthesis of 2.11 – 4-chloropyridine hydrochloride (500 mg, 3.33 mmol), 4-aminophenol 
(364 mg, 3.33 mmol), and sodium hydroxide (333 mg, 8.33 mmol) were dissolved in 
DMSO and the solution was heated to 100 °C, overnight. The solution was then cooled to 
room temperature, poured into an excess of ice-water and extracted with ether (3 x 100 
ml). Combined organic extracts were washed with brine, dried over sodium sulfate, and 
evaporated in vacuo. The crude product was purified via silica gel chromatography using 
a Biotage Isolera One system (linear gradient EtOAc → 5% MeOH/EtOAc) to give 53 mg 
(9% yield) of compound 2.11. 1H NMR (500 MHz, Chloroform-d) δ 8.44 – 8.38 (m, 2H), 
6.89 (d, J = 8.5 Hz, 2H), 6.81 – 6.76 (m, 2H), 6.71 (d, J = 8.5 Hz, 2H), 3.69 (s, 2H). 13C 
NMR (100 MHz, Chloroform-d) δ 165.83, 151.38, 145.88, 144.23, 122.13, 116.37, 111.70. 
HRMS-ESI (m/z): [M + H]+ calcd for C11H10N2O, 187.0866; found 187.0865. 
 
Synthesis of 2.12 – A flame-dried flask was charged with 2-picolinic acid (2 g, 16.2 mmol) 
and sodium bromide (3.3 g, 32.5 mmol). Thionyl chloride (8.2 ml, 114 mmol) was added 
carefully to give a green solution which was refluxed overnight. The solution was then 
cooled to room temperature and the excess thionyl chloride was evaporated in vacuo. 
Methanol (16 ml) was added slowly to the flask and the solution was stirred at room 
temperature for 30 min. The volatiles were then evaporated in vacuo, saturated sodium 
bicarbonate solution was added to the residue and was extracted with EtOAc (3 x 75 ml). 
Combined organic extracts were washed with brine, dried over sodium sulfate, and 
evaporated in vacuo. The crude product was purified via silica gel chromatography using 
a Biotage Isolera One system (linear gradient 25% EtOAc/Hexanes → 33% 
EtOAc/Hexanes) to give 2.1 g (75% yield) of compound 2.12 as a brown solid. 1H NMR 
(500 MHz, Chloroform-d) δ 8.61 (d, J = 5.2 Hz, 1H), 8.10 (t, J = 1.5 Hz, 1H), 7.46 (dt, J = 
5.3, 1.6 Hz, 1H), 3.98 (s, 3H). 13C NMR (100 MHz, Chloroform-d) δ 164.57, 150.57, 
149.18, 145.36, 127.08, 125.59, 53.14. HRMS-ESI (m/z): [M + H]+ calcd for C7H6ClNO2, 
172.0160; found 172.0157. 
 
Synthesis of 2.13 – Compound 2.12 (1.5 g, 8.74 mmol) and anhydrous magnesium chloride 
(416 mg, 4.37 mmol) was added to dry THF (5 ml). After 5 min, a 2M methylamine/THF 
solution (15 ml, 30 mmol) was added dropwise over 10 min. The resultant suspension was 
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stirred at room temperature for 2h, after which water (17 ml) and 1M HCl (9 ml) were 
added. The product was extracted with EtOAc (3 x 50 ml) and the combined organic layers 
were washed with brine, dried over sodium sulfate, and evaporated in vacuo to give 1.46 g 
(98% yield) of compound 2.13 as a yellow oil and was used without further purification. 
1H NMR (500 MHz, Chloroform-d) δ 8.40 (d, J = 5.3 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H), 
7.96 (s, 1H), 7.39 (dd, J = 5.3, 2.0 Hz, 1H), 3.00 (d, J = 5.1 Hz, 3H). 13C NMR (100 MHz, 
Chloroform-d) δ 163.73, 151.35, 148.91, 145.76, 126.16, 122.67, 26.15. HRMS-ESI (m/z): 
[M + H]+ calcd for C7H8ClN2O, 171.0320; found 171.0317. 
  
Synthesis of 2.14 – 4-aminophenol (672 mg, 6.15 mmol) was dissolved in DMF (6 ml) and 
potassium tert-butoxide (697 mg, 6.21 mmol) was added it. The solution was stirred at 
room temperature for 1 hour after which a solution of compound 2.12 (1 g, 5.86 mmol) in 
DMF (3 ml) was added to it. Potassium carbonate (405 mg, 2.93 mmol) was added to the 
combined solution, which was then heated to 80 °C, overnight. The mixture was cooled to 
room temperature, diluted with about 100 ml water and extracted with EtOAc (3 x 50 ml). 
Combined organic extracts were washed with brine, dried over sodium sulfate, and 
evaporated in vacuo. The crude product was purified via silica gel chromatography using 
a Biotage Isolera One system (linear gradient 50% EtOAc/Hexanes → 80% 
EtOAc/Hexanes) to give 820 mg (57% yield) of compound 2.14. 1H NMR (500 MHz, 
Chloroform-d) δ 8.29 (d, J = 5.6 Hz, 1H), 8.06 – 8.00 (m, 1H), 7.64 (d, J = 2.5 Hz, 1H), 
6.90 – 6.80 (m, 3H), 6.66 (d, J = 8.7 Hz, 2H), 3.77 (bs, 2H), 2.96 (d, J = 5.1 Hz, 3H). 13C 
NMR (100 MHz, Chloroform-d) δ 167.10, 164.68, 152.04, 149.47, 145.34, 144.45, 121.81, 
121.70, 116.32, 116.25, 113.65, 109.76, 26.08. HRMS-ESI (m/z): [M + H]+ calcd for 
C13H13N3O2, 244.1081; found 244.1081. [M + Na]
+ calcd for C13H13N3O2, 266.0900; found 
266.0900. 
 
General procedure for SNAr coupling of compounds 2.15, 2.17, and 2.19: 
In a dry flask, the appropriate naphthol or quinolol (1 Eq), 4-fluoronitrobenzene (1.01 Eq), 
and cesium carbonate (1.01 Eq) were dissolved in DMF (0.2 M) and heated to 70 °C. The 
reaction was monitored by TLC (in 70% EtOAc/Hex) and was typically complete in 2 
hours. The solution was cooled to room temperature, poured into water (10x the amount of 
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DMF) and extracted with EtOAc (3x). The combined organics layers were washed with 
10% K2CO3 solution, brine, dried over sodium sulfate, and evaporated in vacuo. The crude 
product was used without further purification or purified via silica gel chromatography 
using a Biotage Isolera One system. 
 
2-(4’-nitrophenoxy)naphthalene (2.15) – β-naphthol (250 mg, 1.73 mmol) was used in this 
reaction and the crude product obtained (444 mg, 97% yield) was used without further 
purification. 
 
6-(4’-nitrophenoxy)quinoline (2.17) – 6-hydroxyquinoline (726 mg, 5 mmol) was used in 
this reaction and the crude product obtained was purified via silica gel chromatography 
using a Biotage Isolera One system (linear gradient Hexanes → 50% EtOAc/Hexanes) to 
give 1159 mg (87% yield) of compound 2.17 as a yellow solid. 1H NMR (500 MHz, 
Chloroform-d) δ 8.90 (dd, J = 4.2, 1.6 Hz, 1H), 8.21 (d, J = 9.1 Hz, 2H), 8.16 (d, J = 9.0 
Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.50 – 7.39 (m, 3H), 7.08 (d, J = 9.0 Hz, 2H). 13C NMR 
(100 MHz, Chloroform-d) δ 162.69, 152.74, 150.15, 145.9, 143.07, 135.40, 132.18, 
129.02, 126.00, 123.59, 121.88, 117.67, 116.21. HRMS-ESI (m/z): [M + H]+ calcd for 
C15H10N2O3, 267.0764; found 267.0765. 
 
7-(4’-nitrophenoxy)quinoline (2.19) – 7-hydroxyquinoline (82 mg, 0.56 mmol) was used 
in this reaction and the crude product obtained was purified via silica gel chromatography 
using a Biotage Isolera One system (linear gradient 20% EtOAc/Hexanes → 40% 
EtOAc/Hexanes) to give 90 mg (60% yield) of compound 2.19 as a light yellow solid. 1H 
NMR (500 MHz, Chloroform-d) δ 8.94 (dd, J = 4.3, 1.6 Hz, 1H), 8.29 – 8.23 (m, 2H), 8.21 
(dd, J = 8.3, 1.6 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.43 (dd, J = 
8.3, 4.3 Hz, 1H), 7.36 (dd, J = 8.9, 2.4 Hz, 1H), 7.19 – 7.13 (m, 2H). 13C NMR (100 MHz, 
Chloroform-d) δ 162.25, 155.79, 151.41, 149.22, 143.29, 135.87, 130.09, 126.01, 125.74, 
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120.78, 120.73, 118.19, 117.72. HRMS-ESI (m/z): [M + H]+ calcd for C15H10N2O3, 
267.0764; found 267.0763. 
 
General procedure for iron reduction of the nitro group to give 2.16, 2.18, and 2.20: 
1 Eq of compound 2.15, 2.17, or 2.19 was suspended in 80% (v/v) EtOH/water (0.2 M) 
followed by the addition of Iron (5 Eq) and 1-2 drops of concentrated HCl. The suspension 
was refluxed and the reaction monitored by TLC (in 70% EtOAc/Hex). The reaction was 
typically complete in 1.5 h, after which the mixture was filtered over celite, and washed 
with EtOAc. The volatiles were evaporated in vacuo, 10% K2CO3 was added and the 
mixture was extracted with EtOAc (3x). The combined organic layers were washed with 
10% K2CO3, brine, dried over sodium sulfate, and evaporated in vacuo. The crude product 
was used without further purification or purified via silica gel chromatography using a 
Biotage Isolera One system. 
 
4-(naphthalen-2-yloxy)aniline (2.16) – Compound 2.15 (445 mg, 1.68 mmol) was used in 
this reaction and the crude product was purified via silica gel chromatography using a 
Biotage Isolera One system (linear gradient Hexanes → 30% EtOAc/Hexanes) to give 249 
mg (63% yield) of compound 2.16 as a brown solid. 1H NMR (500 MHz, Chloroform-d) δ 
7.81 (d, J = 8.6 Hz, 2H), 7.67 (d, J = 8.2 Hz, 1H), 7.48 – 7.40 (m, 1H), 7.38 (td, J = 7.3, 
6.7, 1.2 Hz, 1H), 7.27 (dd, J = 9.0, 2.5 Hz, 1H), 7.18 (d, J = 2.4 Hz, 1H), 7.00 – 6.93 (m, 
2H), 6.77 – 6.70 (m, 2H). 13C NMR (100 MHz, Chloroform-d) δ 156.84, 148.47, 142.84, 
134.32, 129.60, 129.58, 127.63, 126.92, 126.36, 124.15, 121.31, 119.19, 116.27, 111.63 
HRMS-ESI (m/z): [M + H]+ calcd for C16H13NO, 236.1070; found 236.1068. 
 
4-(quinolin-6-yloxy)aniline (2.18) – Compound 2.17 (1000 mg, 3.756) was used in this 
reaction to give 876 mg (98% yield) of 2.18 that was used without further purification. 1H 
NMR (500 MHz, Chloroform-d) δ 8.78 (dd, J = 4.2, 1.5 Hz, 1H), 8.04 (d, J = 9.2 Hz, 1H), 
7.94 (dd, J = 8.3, 1.6 Hz, 1H), 7.47 (dd, J = 9.2, 2.7 Hz, 1H), 7.35 – 7.29 (m, 1H), 7.06 (d, 
J = 2.7 Hz, 1H), 6.97 – 6.91 (m, 2H), 6.75 – 6.69 (m, 2H), 3.68 (s, 2H). 13C NMR (126 
MHz, Chloroform-d) δ 188.00, 157.28, 148.57, 147.83, 144.75, 143.33, 134.99, 131.11, 
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129.10, 122.52, 121.62, 121.40, 116.32, 110.51, 67.25. HRMS-ESI (m/z): [M + H]+ calcd 
for C15H12N2O, 237.1022; found 237.1021. 
 
4-(quinolin-7-yloxy)aniline (2.20) – Compound 2.19 (95 mg, 0.36 mmol) was used in this 
reaction to give 77 mg (91% yield) of 2.20 that was used without further purification. 1H 
NMR (500 MHz, Chloroform-d) δ 8.82 (d, J = 4.2 Hz, 1H), 8.10 (d, J = 8.2 Hz, 1H), 7.76 
(d, J = 8.9 Hz, 1H), 7.39 (d, J = 2.4 Hz, 1H), 7.34 (dd, J = 8.9, 2.4 Hz, 1H), 7.31 – 7.21 (m, 
1H), 6.97 (d, J = 8.3 Hz, 2H), 6.73 (d, J = 8.2 Hz, 2H), 3.60 (s, 2H). 13C NMR (100 MHz, 
Chloroform-d) δ 160.39, 150.72, 149.50, 147.35, 143.48, 135.67, 129.08, 124.06, 121.81, 
119.70, 119.32, 116.30, 112.31. HRMS-ESI (m/z): [M + H]+ calcd for C15H12N2O, 
237.1022; found 237.1022. 
 
Synthesis of 2.21 – para-toluenesulfonic acid (1.48 g, 7.8 mmol) and 6-aminoquinoline 
(325 mg, 2.6 mmol) were dissolved in acetonitrile (10 ml), and the solution was cooled in 
an ice-bath. A solution of sodium nitrite (359 mg, 5.2 mmol) and potassium iodide (1.1 g, 
6.5 mmol) in 1.5 ml water was prepared and added dropwise to the acetonitrile solution 
(highly exothermic reaction). The resultant suspension was allowed to warm to room 
temperature and stirred overnight. 50 ml water was added and the pH adjusted to 9 using 
sodium bicarbonate. Sodium thiosulfate (2M, 5.2 ml) was then added and the suspension 
filtered to give a solid precipitate. The precipitate was dissolved in EtOAc, washed with 
sat. sodium bicarbonate, brine, dried over sodium sulfate, and evaporated in vacuo. The 
orange-red solid obtained (284 mg, 43% yield) was used without further purification. 
HRMS-ESI (m/z): [M + H]+ calcd for C9H6IN, 255.9618; found 255.9616. 
 
Synthesis of 2.22 – compound 2.21 (77 mg, 0.3 mmol), phenylenediamine (97 mg, 0.9 
mmol), Pd2(dba)3 (28 mg, 0.03 mmol), BINAP (37 mg, 0.06 mmol), and sodium tert-
butoxide (86 mg, 0.9 mmol) were added to a flame-dried vial charged with a stirrer. The 
vial was evacuated and back-filled with N2 (3x) and 3 ml Dioxane (0.1 M) was added. The 
vial was sealed and heated to 101 oC for 12 h. The solution was cooled to room temperature, 
poured into water and extracted with EtOAc (3x). The combined organic layers were 
washed with sat. sodium bicarbonate, brine, dried over sodium sulfate, and evaporated in 
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vacuo. The crude product was purified via silica gel chromatography using a Biotage 
Isolera One system (linear gradient 0.1%TEA/39.9% EtOAc/Hexanes → 0.1%TEA/99.9% 
EtOAc) to give 40 mg (57% yield) of compound 2.22. HRMS-ESI (m/z): [M + H]+ calcd 
for C15H13N3, 236.1182; found 236.1180. 
 
General Procedure for formation of the urea to give final products 2.1 – 2.6: 
The appropriate aniline-containing compound (1 Eq) and 2.10 (1 Eq) were added to DMSO 
(0.1 M) followed by the addition of DIEA (1.08 Eq). The resultant slurry was heated at 
60oC and the reaction was monitored by TLC. The reaction was typically complete in 2 h, 
after which the resultant solution was cooled to room temperature and purified directly 
using reverse-phase (C18) column chromatography on a Biotage Isolera One system (linear 
gradient 30% MeCN/H2O → 90% MeCN/H2O). 
 
Compound 2.1 – The reaction was performed using compound 2.11 (11 mg, 58 μmol) and 
gave 16 mg (57% yield) of compound 2.1 as a white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 8.49 – 8.43 (m, 2H), 7.78 (s, 1H), 7.73 (s, 1H), 7.67 (m, 1H), 7.62 – 7.54 
(m, 2H), 7.45 – 7.38 (m, 2H), 7.05 – 6.99 (m, 2H), 6.86 – 6.80 (m, 2H), 3.57 (s, 2H), 2.44 
(s, 8H), 2.29 (s, 3H). HRMS-ESI (m/z): [M + H]+ calcd for C25H26F3N5O2, 486.2111; found 
486.2112. 
 
Compound 2.2 – The reaction was performed using compound 2.14 (14 mg, 58 μmol) and 
gave 18 mg (57% yield) of compound 2.2 as a white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 8.44 (d, J = 5.6 Hz, 1H), 8.37 – 8.30 (m, 2H), 8.20 (s, 1H), 7.69 – 7.60 
(m, 3H), 7.59 (dd, J = 19.9, 2.2 Hz, 2H), 7.39 – 7.33 (m, 2H), 7.13 (dd, J = 5.6, 2.5 Hz, 
1H), 6.99 – 6.94 (m, 2H), 3.59 – 3.55 (m, 2H), 3.05 (d, J = 5.1 Hz, 3H), 2.48 (s, 3H), 2.43 
(s, 2H), 2.30 (d, J = 1.3 Hz, 4H). HRMS-ESI (m/z): [M + H]+ calcd for C27H29F3N6O3, 
543.2326; found 543.2321. 
 
Compound 2.3 – The reaction was performed using compound 2.16 (24 mg, 0.1 mmol) and 
gave 28 mg (53% yield) of compound 2.3 as a white solid. 1H NMR (500 MHz, DMSO-
d6) δ 9.01 (s, 1H), 8.82 (s, 1H), 7.99 – 7.87 (m, 3H), 7.79 (d, J = 8.1 Hz, 1H), 7.65 – 7.38 
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(m, 7H), 7.28 (dd, J = 4.8, 2.3 Hz, 2H), 7.07 (d, J = 8.9 Hz, 2H), 3.52 (s, 2H), 2.36 (s, 9H), 
2.16 (s, 3H). HRMS-ESI (m/z): [M + H]+ calcd for C30H29F3N4O2, 535.2315; found 
535.2315. 
 
Compound 2.4 – The reaction was performed using compound 2.18 (59 mg, 0.25 mmol) 
and gave a 20% yield of compound 2.4 as a white solid. 1H NMR (500 MHz, Chloroform-
d) δ 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.07 (d, J = 9.1 Hz, 1H), 8.00 (dd, J = 8.3, 1.6 Hz, 1H), 
7.75 (s, 1H), 7.68 – 7.60 (m, 2H), 7.60 – 7.52 (m, 2H), 7.44 (dd, J = 9.2, 2.7 Hz, 1H), 7.43 
– 7.31 (m, 3H), 7.18 (d, J = 2.7 Hz, 1H), 7.06 – 6.98 (m, 2H), 3.55 (s, 2H), 2.45 (s, 7H), 
2.28 (s, 3H). HRMS-ESI (m/z): [M + H]+ calcd for C29H28F3N5O2, 536.2268; found 
536.2268. 
 
Compound 2.5 – The reaction was performed using compound 2.20 (24 mg, 0.1 mmol) and 
gave 20 mg (34% yield) of compound 2.5 as a white solid. 1H NMR (500 MHz, DMSO-
d6) δ 9.05 (s, 1H), 8.88 (s, 1H), 8.82 (dd, J = 4.2, 1.7 Hz, 1H), 8.34 (dd, J = 8.3, 1.7 Hz, 
1H), 8.04 – 7.95 (m, 2H), 7.62 (d, J = 8.5 Hz, 1H), 7.61 – 7.53 (m, 3H), 7.42 (ddd, J = 
13.1, 8.6, 3.4 Hz, 2H), 7.14 (d, J = 8.9 Hz, 2H), 3.53 (s, 2H), 2.37 (s, 8H), 2.15 (s, 3H). 
HRMS-ESI (m/z): [M + H]+ calcd for C29H28F3N5O2, 536.2268; found 536.2271. 
 
Compound 2.6 – The reaction was performed using compound 2.22 (20 mg, 85 μmol) and 
gave 10.2 mg (22% yield) of compound 2.6 as a white solid. HRMS-ESI (m/z): [M + H]+ 
calcd for C29H29F3N6O, 535.2428; found 535.2429. 
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Synthesis of 2.7 – Compound 2.18 (50 mg, 0.21 mmol) was dissolved in THF (2 ml) and 
3-trifluoromethylphenyl isocyanate (31 μL, 0.22 mmol) was added to it to give a fine 
slurry. Triethylamine (31 μL, 0.22 mmol) was then added and the solution was refluxed 
overnight. EtOAc was added to the flask and the organic layer was washed with 10% 
K2CO3, brine, dried over sodium sulfate, and evaporated in vacuo. The crude product was 
purified via reverse phase HPLC (linear gradient 30% MeCN/H2O → 90% MeCN/H2O) to 
give 17 mg (18% yield) of compound 2.7 as a white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 8.80 (dd, J = 4.3, 1.7 Hz, 1H), 8.06 (d, J = 9.1 Hz, 1H), 7.97 (ddd, J = 8.2, 
1.8, 0.8 Hz, 1H), 7.49 (dd, J = 9.2, 2.8 Hz, 1H), 7.34 (dd, J = 8.3, 4.2 Hz, 1H), 7.08 (d, J = 
2.7 Hz, 1H), 7.01 – 6.93 (m, 2H), 6.79 – 6.72 (m, 2H). 19F NMR (376 MHz, Chloroform-
d) δ -63.02. HRMS-ESI (m/z): [M + H]+ calcd for C23H16F3N3O2, 424.1267; found 
424.1267. 
 
Synthesis of 2.23 – 4-formylbenzoic acid (1.5 g, 10 mmol) was dissolved in anhydrous 
methanol (30 ml) and the solution was cooled in an ice-bath. Acetyl chloride (7.1 ml, 100 
mmol) was added dropwise and the reaction was allowed to warm to room temperature and 
stirred overnight. The volatiles were evaporated in vacuo, the residue dissolved in EtOAc 
(200 ml) and washed with 1N NaOH (5 x 50 ml), brine (3 x 50 ml), dried over sodium 
Scheme 2.2. Synthesis of compounds 2.7 – 2.9. 
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sulfate, and evaporated in vacuo. 1.6 g (97% yield) of crude product was obtained and was 
carried forward without further purification.  
 
Synthesis of 2.24 – Sodium borohydride (746 mg, 19.7 mmol) was added to chloroform (8 
ml) and cooled in an ice-bath. Acetic acid (5.2 ml, 91 mmol) was then added and the 
reaction was stirred for 1.5 h on ice. A solution of 2.23 (1.6 g, 9.76 mmol) and N-
methylpiperazine (1 ml, 9.3 mmol) in chloroform (2 ml) was then added to it and stirring 
was continued on ice for 1 h and at room temperature for 12 h. 5 ml water was then added 
to it and the pH adjusted to 9 using 10% sodium carbonate. The aqueous mixture was 
extracted with DCM (2x). The combined organic layers were washed with water, brine, 
dried over sodium sulfate, and evaporated in vacuo. The crude product obtained (2.3 g, 
100% yield) was carried forward without further purification.  
 
Synthesis of 2.25 – Compound 2.24 (2.3 g, 9.26 mmol) was added to conc. HCl (16 ml) 
and the solution refluxed for 5 h. The resultant suspension was cooled to 45 °C and filtered. 
The filter cake was washed with isopropanol and dried to give 1.55 g (54% yield) of 
compound 2.25 as a yellow-white crystalline solid.  HRMS-ESI (m/z): [M + H]+ calcd for 
C13H18N2O2, 235.1441; found 235.1441. 
 
Synthesis of 2.8 – Compound 2.25 (52 mg, 0.17 mmol), diphenylphosphoryl azide (38 μL, 
0.17 mmol) and triethylamine (118 μL, 0.85 mmol) were added to Toluene (1 ml) and 
refluxed for 1 h. Compound 2.18 (20 mg, 0.08 mmol) was then added and the refluxed 
continued for 2 h. The reaction was cooled to room temperature, toluene was evaporated 
in vacuo, and the crude product was purified directly purified via reverse phase HPLC 
(linear gradient 5% MeCN/H2O → 90% MeCN/H2O).  9.6 mg (24% yield) of compound 
2.28 was obtained as a white solid.  HRMS-ESI (m/z): [M + H]+ calcd for C28H29N5O2, 
468.2394; found 468.2392. 
 
Compound 2.26 was synthesized by Kristin Ko. 
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Synthesis of 2.9 – Compounds 2.18 (47 mg, 0.2 mmol), 2.26 (162 mg, 0.4 mmol), and 
DIEA (143 μL, 0.8 mmol) were added to DMA (2 ml) and stirred at 40 °C for 3 h. The 
reaction mixture was cooled to room temperature, poured into 10% K2CO3, and extracted 
with EtOAc (3x). The combined organic layers were washed with brine, dried over sodium 
sulfate, and evaporated in vacuo. The crude product was purified using reverse-phase (C18) 
column chromatography on a Biotage Isolera One system (linear gradient 40% MeCN/H2O 
→ 100% MeCN) to give 64 mg (65% yield) of compound 2.9 as a white solid. 1H NMR 
(500 MHz, Chloroform-d) δ 8.80 (dd, J = 4.3, 1.7 Hz, 1H), 8.07 (d, J = 9.1 Hz, 1H), 7.99 
(ddd, J = 8.4, 1.7, 0.8 Hz, 1H), 7.46 (dd, J = 9.2, 2.8 Hz, 1H), 7.37 (dd, J = 8.3, 4.2 Hz, 
1H), 7.34 – 7.23 (m, 4H), 7.26 – 7.15 (m, 2H), 7.15 – 7.07 (m, 2H), 7.08 – 7.00 (m, 2H), 
6.61 (s, 1H), 6.41 (s, 1H), 2.34 (s, 3H), 1.37 (s, 9H). HRMS-ESI (m/z): [M + H]+ calcd for 
C30H29N5O2, 492.2394; found 492.2392. 
Spectral Data 
Spectral data for all compounds in this chapter are shown in Appendix A.  
General Biochemical Methods 
Black, opaque-bottom 96 well plates were used for fluorescence assays and were 
purchased from Nunc.  c-Src, c-Abl, T315I Abl, and Y253F Abl were expressed in E. coli 
by Christel Fox and Frank Kwarcinski using previously published procedures.42  c-Abl 
numbering is based on the 1b isoform. Data was obtained using a Biotek Synergy 4 plate 
reader.  Curve fitting was performed using GraphPad Prism 4 software. 
Determination of Inhibitor IC50 
 A previously reported continuous fluorescence assay was used to determine 
inhibitor IC50 values.
43 Reaction volumes of 100 μL were used in 96-well plates. 85 μL of 
enzyme in buffer mix was added to each well followed by 2.5 μL of the appropriate 
inhibitor dilution (typically 360, 120, 40, 13.33, 4.44, 1.48, 0.49, 0.164, and 0.055 Μm in 
DMSO) and 2.5 μL of a substrate peptide solution (typically 1.8 mM in DMSO for the c-
Src substrate and 2.4 mM in DMSO for the substrate of c-Abl and its mutants). The reaction 
was initiated with 10 μL of ATP (50 mM or 1 mM in water), and reaction progress was 
immediately monitored at 405 nm (ex. 340 nm) for 10 min. Each well had a final 
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concentration of 30 nM c-Src or c-Abl, 45 μM c-Src substrate or 60 μM c-Abl substrate, 
100 μM or 5 mM ATP, 100 μM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, and 
0.01% Triton X-100.  
The initial-rate data collected was used for determination Ki values. For Ki determination, 
the kinetic values were obtained directly from nonlinear regression of substrate-velocity 
curves in the presence of various concentrations of the inhibitor. The equation Y = Bottom 
+ (Top – Bottom)/(1 + 10^X – LogEC50), X = log(concentration) and Y = binding; was 
used in the nonlinear regression. The Ki value was determined using > 3 independent 
experiments. The mean Ki value is reported in this chapter and the mean, standard 
deviation, and a representative curve for each inhibitor is reported in Appendix A.  
 
Representative curves for compound 2.4 
Average Ki = 216 ± 60 nM (wt Src), Titrates enzyme (IC50 ̴ 30 nM) for wt, T315I, and 
Y253F Abl  
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Correlating Selectivity Score to Kd values 
A plot of the selectivity score observed in a primary screen versus the Kd values for 
each individual target aides in choosing the selectivity score which best represents targets 
inhibited at or below the screening concentration. Figure 2.8 shows that for a compound 
screened at 1 μM, an S(35) score includes targets with a Kd greater than 10-fold the 
screening concentration. An S(10) score, however, mostly includes targets with a Kd equal 
or below the screening concentration of 1 μM 
 
 
 
 
 
 
Figure 2.8. A plot of the primary screen score versus Kd values for individual targets. The 
blue marks targets with a Kd value of 1 μM. An S(10) only includes targets with a Kd value 
below the screening concentration of 1 μM. 
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CHAPTER III 
Development of Cyclic Peptides as Inhibitors of Grb2 SH2 
3.1. Abstract 
 Growth factor receptor bound protein 2 (Grb2) is an adaptor protein linking 
extracellular signals to intracellular signaling cascades critical for cell growth. Its key role 
in Ras-signaling has made it an attractive target for targeted therapy in cancer. Current 
inhibitors of Grb2, however, suffer from poor cellular efficacy, which is likely a 
consequence of most such inhibitors being primarily based on a single scaffold.  
This chapter details a comprehensive effort in developing potent inhibitors of the 
SH2 domain of Grb2 based on the motif of its endogenous binding partner. We 
hypothesized that utilizing conformational constraint for inhibitor development could lead 
to compounds with increased potency due to a lowered entropic cost of binding. 
Furthermore, we believed constraint through macrolactamization to be an effective method 
in increasing cell permeability and efficacy in whole cells.  
Using the consensus sequence for Grb2 SH2 binding, a series of phosphotyrosine-
containing cyclic peptides with increasing macrocycle size were synthesized. An optimal 
26-membered macrocycle, 3.5, identified through a fluorescence polarization assay was 
then modified by replacing the phosphotyrosine motif with a variety of mimetics. A 
phosphatase-stable analog, compound 3.10, was found to be the most potent of these 
mimetics and was analyzed biophysically and in cellulo. Surface plasmon resonance and 
Isothermal titration calorimetry revealed 3.10 to have a markedly increased potency 
compared to its linear analogs. This increase in potency was driven entirely by a lowered 
entropic cost of binding to the protein, thereby, validating our hypothesis. Analysis of the 
kinetics of binding revealed compound 3.10 to have a slower dissociation rate than its linear 
counterpart, adding insight into the role of conformational restriction in altering the 
residence time of a ligand. Furthermore, compound 3.10 was shown to possess in cellulo 
activity in K562 cells while its linear analog did not, suggesting that the global 
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conformational restriction could indeed aid in the promotion of intramolecular H-bonds, 
thereby increasing cell permeability and cellular efficacy. Our effort in understanding the 
thermodynamics and kinetics of ligand-binding to Grb2 SH2 has set the stage for the 
further development of efficacious inhibitors, thereby, realizing the opportunity of 
targeting Grb2 in the treatment of cancer.   
3.2. Role of Grb2 in Cell Signaling 
In 1992, Lowenstein et al. identified the missing link connecting EGF stimulation 
of cells with their phenotypically observed response of growth.1 Grb2 was identified from 
a phage display library as an adaptor protein, linking EGFR to the Ras signaling cascade, 
thereby completing the delineation of one of the most important signaling pathways 
Figure 3.1. Grb2 is comprised of one SH2 domain 
flanked by two SH3 domains. The SH2 domain binds 
a peptide with a pYXNX motif in a β-turn 
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involved in cell growth. This discovery led to the rapid characterization of Grb2, and it was 
observed to be a 25 kDa protein comprised of one SH2 domain flanked by N-terminal and 
C-terminal SH3 domains (Figure 3.1). The SH2 domain consists of a central antiparallel 
β-sheet flanked by two helices and specifically binds peptides with a pYXNX motif in a β-
turn. The SH3 domains, which share 34% sequence identity and are primarily composed 
of β-sheets, both bind to peptides with a polyproline type II (PPII) helix with differing 
selectivity.2  
A substantial amount of cytosolic Grb2 is associated with the PPII helix of the Son 
of Sevenless (Sos) protein via its SH3 domains. Upon EGF stimulation and receptor 
phosphorylation, the Grb2-Sos complex binds via the Grb2 SH2 domain either directly or 
indirectly to EGFR. Direct binding is achieved through the pY1068 or pY1086 residue of 
EGFR, while indirect binding is mediated via a tyrosine phosphorylated protein, Shc, 
which itself binds to pY1148 of EGFR.3 This results in membrane localization of Sos, 
which functions as a guanine nucleotide exchange factor (GEF), and loads membrane-
bound Ras with GTP thus activating it, leading to the propagation of the activating signal 
downstream.1, 4-5 
While the role of Grb2 within the above-mentioned pathway is the most extensively 
characterized, later discoveries have expanded its functional role to several other pathways. 
Grb2 SH2 can bind to several other RTKs such as Her-2, Her-3, PDGFR, c-Met and FGFR-
2,6 and to other phosphorylated proteins such as β4 integrin, IRS-17, BCR-Abl and FAK 
either directly or indirectly through linker proteins such as Shc and SHP-2. Furthermore, 
in addition to Sos, many other effector molecules, such as the GEFs (C3G, VAV), receptors 
(CD28), adaptor proteins (Cbl, Slp-76), phosphotyrosine phosphatases (SHP2) and 
serine/threonine kinases (PAK1, MEKK1) can bind to the SH3 domains of Grb2.7 The 
astounding number of binding partners of both the SH2 and SH3 domains of Grb2 provide 
for an incredible degree of cross-talk between various signaling pathways, which may be 
highly dependent on temporal and spatial factors as well as differential concentrations in 
diverse cell types. 
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3.3. Grb2 as a Therapeutic Target in Cancer 
Due to its critical role in several signaling pathways, Grb2 is considered a putative 
therapeutic target in several cancers. The fusion protein, Bcr-Abl, discussed in detail in 
Chapter II binds to the Grb2 SH2 domain through a phosphorylated tyrosine residue (Y177) 
in the Bcr region and implicates Ras signaling in CML. A Y177F mutant is unable to 
transform primary bone marrow cultures underscoring the role of Grb2 in CML 
progression.8 While the FDA-approved inhibitors and compound 2.4 are very successful at 
inhibiting Bcr-Abl in cellulo and in the clinic, resistance eventually develops rendering 
these molecules ineffective. In addition to the innate forms of resistance, such as through 
the T315I mutation (discussed in Chapter II), long-term sequential therapy gives rise to 
acquired resistance through the emergence of double-mutants which render all CML drugs 
ineffective.9-10 Combination therapy with ‘drug cocktails’ comprising of a Bcr-Abl 
inhibitor and Grb2 inhibitor could be advantageous in preventing or slowing the emergence 
of drug-induced resistance.   
Furthermore, Grb2 is overexpressed in several breast cancer cell lines and tissue 
samples.11-12 The most marked overexpression is observed in the MCF-7, MDA-MB-361, 
and MDA-MB-453 cell lines in comparison to human mammary epithelial (HME) cells 
and the majority of breast cancer cell lines.11 Within the context of breast cancer, the major 
role of Grb2 is related to cell adhesion, motility, and invasion rather than growth and 
proliferation.13 This suggests that Grb2 is a putative target for the inhibition of tumor 
metastasis in invasive breast cancer. 
Antisense oligonucleotides have demonstrated the efficacy of silencing Grb2 in Ph+ 
leukemia cells14 and in breast cancer cells expressing high levels of Her2 (MDA-MB-453 
and SKBr3)15 paving the way for intervention using small molecules and peptides.     
3.4. Current Inhibitors of Grb2 
The SH2 domain of Grb2 binds phosphotyrosine-containing peptides in a β turn 
with micromolar potencies.16 About 50% of the binding energy is proposed to originate 
from the phosphotyrosine residue while the residues C-terminal to it control specificity 
among SH2 domains.17-18 The SH3 domain forms weak interactions over a relatively flat 
and hydrophobic surface with a polyproline type-II helix-containing binding partner.19-20 
The high-affinity handle of a phosphotyrosine residue and the specificity that can be 
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achieved has made the SH2 domain a more attractive target for inhibitor development than 
the SH3 domain.  
Despite the relative ‘druggability’ of the SH2 domain, inhibitor development has 
primarily focused on a few scaffolds with limited success. The first, disclosed by Novartis, 
consists of a 1-aminocyclohexanecarboxylic acid at the pY+1 position to stabilize a β turn 
and a C-terminus 3-napthalen-1-yl-propyl group.21-22 Burke and co-workers have 
extensively modified each segment of the Novartis scaffold from the point of view of 
increasing potency through functional group modifications and imposing conformational 
constraints as well as to increase stability towards phosphatases (Figure 3.2).23-27 Despite 
the large number of analogs that have been synthesized only a few modifications have 
shown an improvement in potency and the most effective compounds retain the 
characteristics of the original Novartis scaffold.28 Moreover, compounds with low 
nanomolar affinity for Grb2 SH2, show a significant reduction in potency in cellulo, 
presumably due to poor cell permeability. The compounds that do show activity, typically 
do so under non-standard conditions such as daily dosing for extended periods of time and 
under serum-starved conditions.29-31  
Figure 3.2. Novartis scaffold and the analogs synthesized by Burke and coworkers. 
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The second scaffold to be explored, termed G1, was obtained from a disulfide-
cyclized phage library.32 G1, and its thioether analog, G1TE, which have potencies in the 
range of 10 to 25 µM, are noteworthy in that they lack a phosphotyrosine residue. While 
these analogs themselves show no activity in cellulo the finding that non-phosphorylated 
compounds could inhibit Grb2 SH2 spurred interest in the further development of this 
scaffold. Optimization and modification of the scaffold, however, did not significantly 
increase potency and the initial promise of circumventing the poor permeability associated 
with di-anionic inhibitors was not realized. A few analogs with low nanomolar potencies 
rely on a phosphotyrosine mimic and are di-anionic in nature.33-34  
Lastly, a class of compounds, relatively underexplored for its in cellulo potential is 
that of conformationally restricted peptides based on the consensus binding sequence of 
Grb2 SH2 (Figure 3.3). Conformational constraint applied locally to the phosphotyrosine 
residue has typically led to a significant loss in potency.35 While global constraint through 
macrocyclization has shown to increase potency and has been studied from a 
thermodynamic standpoint,36 a systematic study of the effect of macrocycle size on potency 
and in cellulo efficacy is lacking.36-38 Consequently, we sought to employ conformational 
restriction as a means to develop potent inhibitors of Grb2 SH2 and to assess these 
inhibitors using biophysical methods and in cellulo. 
 
 
Figure 3.3. Examples of local (left) and global (right) 
conformational constraint in the development of Grb2 SH2 
inhibitors. 
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3.5. Utilizing Conformational Constraint in the Development of Grb2 SH2 Inhibitors 
Conformational constraint, when applied correctly, has long been believed to 
increase the potency of a ligand. The rationale, rooted in the thermodynamics of a protein-
ligand interaction, is that pre-organizing a ligand and restricting its degrees of freedom 
would lead to a smaller entropic change on binding to the protein (Figure 3.4).36, 39 
Provided that the constrained and unconstrained ligands are able to make optimal 
interactions with the protein (∆H for the pair of ligands is the same), a lower entropic cost 
for the constrained ligand would be reflected in a lower free energy of binding.  
Several distinct examples of improved potency using conformational constraint 
have been observed over the last decade.40-41 We reasoned that conformational restriction 
through peptide macrocyclization was ideally suited for the development of inhibitors of 
the Grb2 SH2 domain. In addition to the advantage of increased potency, macrocyclization 
offers an avenue for achieving selectivity for Grb2 SH2. Of the 120 SH2 domains encoded 
in the human genome, the vast majority bind a phosphotyrosine-containing peptide in an 
extended conformation.42 Cyclic peptides would be unable to adopt an extended 
conformation and would be preferred by Grb2 SH2, which binds peptides in a β-turn 
conformation. Furthermore, cyclization could promote the formation of intramolecular H-
bonds which could aid in increasing the permeability of these inhibitors.  
3.6. Macrocycle Optimization 
Our synthetic strategy, based on that described by the Hruby group,43 involved the 
use of an α-Fmoc Ɛ-Alloc protected Lysine at the N-terminus and a Fmoc β-allyl protected 
Aspartic acid at the C-terminus. Both amino acids were compatible with and orthogonal to 
Figure 3.4. The thermodynamic rationale of ligand pre-organization. 
The subscript u indicates an unconstrained ligand and c indicates a 
constrained ligand.   
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Fmoc SPPS and precluded the need for unnatural amino acids as are often required for 
peptide stapling. Deprotection of the allyl/alloc protecting groups was carried out using 
tetrakis(triphenylphosphine)palladium(0) and N,N-dimethylbarbituric acid and cyclization 
was carried out on-resin, prior to cleavage, using standard coupling conditions.  
Macrocycles of increasing length were synthesized as shown in Table 3.1. Glycine 
residues were incorporated with increasing macrocycle size to allow added flexibility to 
accommodate optimal interactions with the protein surface. Biochemical inhibition was 
measured by using a fluorescence polarization assay. Increasing the size of the macrocycle 
from 17 atoms (compound 3.1) to 26 atoms (compound 3.5) led to a dramatic increase in 
potency. Further increasing the size of the macrocycle or altering the position of the glycine 
residue (compounds 3.6 – 3.9), resulted in a plateau or slight decrease in potency. This 
could be rationalized by the fact that an increase in size would be required to make 
appropriate contacts with the so-called hot spots at the protein surface. After a point, 
however, any increase in macrocycle size would result in a loss of effective pre-
organization, and any increase in enthalpy would be compensated by a greater entropic 
penalty paid for binding to the protein. 
Table 3.1. Summary of IC50 values of macrocycles of 
increasing size 
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3.7. Use of Phosphotyrosine Mimetics 
Compound 3.5 with 26 atoms and an i→i+6 linkage was the most potent with an 
IC50 of 0.7 µM. We next sought to replace the phosphotyrosine residue with a non-
hydrolysable phosphotyrosine (pY) mimetic to enable the use of this compound in cellulo.  
Burke and coworkers have successfully used di-anionic residues such as 
phosphonomethyl phenylalanine (Pmp) and p-malonyl phenylalanine (Pmf) as pY 
mimetics for SH2 domains,31, 44-45 and difluorophosphonomethyl phenylalanine (F2Pmp) 
as a pY mimetic for phosphatases.46 Of these mimetics, compound 3.10, with Pmp showed 
Table 3.2. IC50 values of compounds 
with phosphotyrosine mimetics 
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the greatest potency with an IC50 of 540 nM (Table 3.2). This slight increase in potency is 
in agreement with a similar replacement on the Novartis scaffold.47  
In contrast to a previous report which showed a 2 to 8-fold loss in potency on 
substituting Pmp with Pmf,31 we observed a 350-fold reduction in potency for the same 
replacement (compound 3.12) suggesting that the use of this mimetic may be scaffold-
specific.  
Yao and coworkers have shown that an isoxazolecarboxylic acid-containing 
compound could inhibit the STAT3 SH2 domain. Though the affinity of their compound 
was low, only a small loss in potency was observed when compared to a similar 
phosphotyrosine-containing compound.48 Consequently, we attempted replacing the 
phosphate group with mono-anionic mimetics that would result in the reduction of the net 
charge of the molecule and could aid in improving cell permeability. The replacement with 
mimetics such as carboxymethytyrosine (Cmt) in compound 3.13 and p-
(isoxazolecarboxylic acid)phenylalanine (Icaf) in compound 3.14, however, resulted in 
poor to no inhibition. This result underscores the difficulty in developing mono-anionic 
inhibitors of Grb2 SH2 and that phosphotyrosine mimetics are not equally effective across 
SH2 domains since these domains are not necessarily optimized for ligand binding.16  
3.8. Surface Plasmon Resonance Studies 
While a fluorescence polarization assay is useful for ranking compounds based on 
their IC50 values, its ability to determine accurate Ki values for inhibitors is limited by the 
Kd of the probe. To determine whether cyclization did actually provide the hypothesized 
increase in potency and to obtain accurate Kd values, the linear and cyclic Pmp analogs, 
compounds 3.10 and 3.15, were tested against immobilized Grb2 SH2 using surface 
plasmon resonance (SPR).  
Both compounds showed rapid association rates, attaining equilibrium in under a 
minute. Compound 3.10 (Figure 3.5) showed a slightly larger ka of 2.70x10
5 M-1s-1, 
approximately 2-fold greater than that of compound 3.15 (Figure 3.6). Compound 3.10 
does, however, have a markedly slower off-rate (0.0562 s-1) as compared to its linear 
counterpart (0.638 s-1). In a set of similar ligands, a slower off-rate is typically observed in 
one if a conformational change is required for dissociation. This 11-fold faster off-rate for 
55 
 
compound 3.15 could arise from its increased flexibility allowing a conformational change 
to occur rapidly during dissociation.  
Satisfactorily, the slower off-rate for compound 3.10 is translated into a 20-fold 
enhancement in potency (Kd = 207 nM as compared to 4.3µM for 3.15). The Kd values 
obtained from the kinetic analysis were validated using an equilibrium analysis, and the 
curves are shown in Appendix B.  
Figure 3.5. SPR kinetic data for cyclic peptide 3.10. KD = 207.7 ± 0.7 nM, ka (M
-1s-1) = 
2.70x105, kd (s
-1)= 0.0562, Rmax = 60.33, Res SD = 3.43 RU 
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3.9. Isothermal Titration Calorimetry 
Martin and co-workers have argued that conformational constraint doesn’t 
necessarily lead to a lowered entropic cost on binding and that the observed enhancement 
in potency could, in fact, be due to a lower enthalpic component. Using isothermal titration 
calorimetry (ITC) they have compared a series of constrained and unconstrained analogs 
to delineate the energetic components on binding to Grb2 SH2. Their argument, counter to 
Figure 3.6. SPR kinetic data for linear peptide 3.15. KD = 4.274 ± 0.009 µM, ka (M
-1s-1) = 
1.493x105, kd (s
-1)= 0.638, Rmax = 57.92, Res SD = 1.087 RU 
57 
 
conventional wisdom suggests that conformational constraint could lead to more favorable 
binding interactions as compared to the unconstrained analog, which in turn would increase 
the entropic penalty paid upon binding.36, 39, 49 
To demonstrate the increased potency of compound 3.10 was indeed due to a 
lowered entropic cost, we sought to measure the energetic components of the binding 
Figure 3.7. ITC comparison of cyclic and linear peptides. 
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interaction. For the enthalpic and entropic values of two ligands to be directly comparable, 
it is essential that the molecular weights of the ligands are as close to each other as possible. 
Consequently, we synthesized compound 3.16 which retained the same functional groups 
as 3.10 and differed in molecular weight by 1 Da.   
As seen in Figure 3.7, the Kd value of compound 3.10 obtained is almost identical 
to, and in good agreement with, the value obtained from kinetic analysis using SPR. 
Moreover, the change in enthalpy on binding for each compound is within error of each 
other, and the observed enhancement in potency is solely driven by a more favorable 
entropic term. These data suggest that cyclization does indeed lower the entropic cost 
associated with binding and underscores the importance of optimizing the size of the 
macrocycle to achieve a maximum enhancement in potency.    
3.10. Inhibition of Cancer Cell Growth 
As described in Section 3.3, Grb2 plays a role in gowth and proliferation of tumor 
cells in CML. Consequently, to assess the efficacy of cyclic and linear compounds 3.10 
and 3.15 on cell growth, they were tested in the Bcr-Abl dependent K562 cell line. 
Compound 3.10 showed a GI50 of 19 μM after 72 hours of exposure, while its linear 
analog, compound 3.15, showed no inhibition below 100 μM. Furthermore, the low 
nanomolar inhibitor TB01 (see Figure 3.2) has been tested in K562 cells by Burke and 
coworkers with an observed GI50 of 39 µM.
28 A ratio of the cellular to biochemical IC50s 
can offer a measure of the permeability of a compound. Compound 3.10 with a ratio of 100 
does significantly better than TB01, which has a ratio of about 5000.28, 50 This improved 
cellular efficacy of 3.10 compared to compounds 3.15 and TB01 can be attributed to its 
biochemical potency coupled with an increase in cell permeability due to the promotion of 
intramolecular H-bond formation. 
3.11. Conclusions 
Despite the crucial role of Grb2 in cellular growth signaling cascades, relatively 
few SH2 domain-targeting scaffolds have been examined. Through the systematic 
development of conformationally constrained cyclic peptides, we have identified a novel 
scaffold for the inhibition of Grb2 SH2. A detailed analysis of the kinetic and 
thermodynamic parameters of binding of compound 3.10 indicates a significant 
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enhancement in potency compared to its linear counterpart. This enhancement in potency 
is entirely driven by a lower entropic cost upon binding and results in a slower dissociation 
rate upon binding. Furthermore, a significant improvement in cellular permeability is 
achieved validating our hypothesis that conformational restriction could be an attractive 
means for developing cell-permeable inhibitors of Grb2 SH2. 
3.12. Materials and Methods 
General Synthetic Methods 
Unless otherwise noted, all reagents were obtained via commercial sources and 
used without further purification. Tetrahydrofuran (THF) and dichloromethane (CH2Cl2) 
were dried over alumina under a nitrogen atmosphere. 1H and 13C NMR spectra were 
measured with a Varian MR400, Varian VNMRS 500, or Inova 500 spectrometer. Mass 
Spectrometry (HRMS) was carried out by the University of Michigan Mass Spectrometry 
Facility (J. Windak, director). A detailed protocol for the synthesis of cyclic peptides and 
characterization data is provided in Appendix B. 
 
General Biochemical Methods 
Black, opaque-bottom, half-area 96 well plates were used for fluorescence 
polarization assays and were purchased from Nunc.  Grb2 SH2 was expressed in E. coli 
and purified as a monomer by Christel Fox using previously published procedures. Data 
was obtained using a Biotek Synergy 4 plate reader.  Curve fitting was performed using 
GraphPad Prism 4 software. 
 
Kd Determination of the Probe used in Fluorescence Polarization Assays 
In a Costar® 96-well black plate, 55 µL water was added to each well, followed by 
5 µL of probe (1 µM in DMSO). 40 µL of the appropriate dilution of Grb2 SH2 in 2.5x 
buffer (50 mM Na2HPO4/NaH2PO4, 250 mM NaCl, 0.125% Tween-20) was then added 
and the plate incubated on ice for 45 min. Each well contained a final concentration of 50 
nM probe; 12, 6, 3, 1.5, 0.75, 0.375, 0.187, 0.09, 0.46, 0.023, 0.011 or 0 µM Grb2 SH2 in 
20 mM Na2HPO4/NaH2PO4 [pH 7.4], 100 mM NaCl, 0.05% Tween-20, 5% DMSO. The 
plate was then placed into a Biotek® Synergy 4 spectrophotometric plate reader and 
fluorescence polarization was measured with excitation at 485 nm (bandwidth = 20 nm) 
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and emission at 528 nm (bandwidth = 20 nm). The millipolarization (mP) value was 
converted to % Bound using the equation: % Bound = (mPx - mPL)*100/(mPH - mPL) 
where mPx is the polarization value for concentration x, mPL is the lowest polarization 
value for the no-protein control where the probe is completely unbound and mPH is the 
highest polarization value where the probe is completely bound. The equation Y = 
Bmax*X/(Kd + X) was used in the nonlinear regression and an average Kd of three 
independent runs was obtained. 
 
Procedure for the Determination of IC50 Values of Inhibitors 
Competition assays were carried out in a Costar® 96-well black plate with a final 
volume of 100 µL. To each well was added 45 µL water, 2.5 µL of the appropriate dilution 
of inhibitor in DMSO, 2.5 µL of probe (1 µM) and 50 µL Grb2 SH2 (3 µM) in buffer 2X 
(or only buffer 2x without Grb2 SH2 for the no-protein control) and the plate incubated on 
ice for 45 min. Each well contained a final concentration of 25 nM probe; 1.5 µM Grb2 
SH2; 100, 50, 25, 12.5, 6, 3, 1.5, 0.78, 0.39, 0.19 or 0 µM inhibitor; in 20 mM 
Na2HPO4/NaH2PO4 [pH 7.4], 100 mM NaCl, 0.05% Tween-20, 5% DMSO. The plate 
was then placed into a Biotek® Synergy 4 spectrophotometric plate reader and 
fluorescence polarization was measured with excitation at 485 nm (bandwidth = 20 nm) 
and emission at 528 nm (bandwidth = 20 nm). The millipolarization (mP) value was 
converted to % Probe Bound using the equation: % Probe Bound = (mPx - 
mPL)*100/(mPH - mPL) where mPx is the polarization value for inhibitor concentration 
x, mPL is the lowest polarization value for the no-protein control where the probe is 
completely unbound and mPH is the highest polarization value for the no-inhibitor control 
where the probe is >90% bound. The equation Y=Bottom + (Top-Bottom)/(1+10^(X-
LogIC50)) was used in the nonlinear regression. The IC50 value was determined using > 3 
independent experiments. Average IC50 values, standard deviations, and representative 
curves for each compound is included in Appendix B. 
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Representative IC50 curve for compound 3.10 
 
Average IC50 = 0.54 ± 0.04 μM 
 
Surface Plasmon Resonance 
The surface plasmon resonance experiments were performed using a SensiQ® 
Pioneer instrument on a COOH5 chip (high density, hydrogel-based, three-dimensional 
carboxylated surface) containing 3 channels in series. 
Grb2 SH2 (10 kDa) was immobilized on channel 1 (CH 1), and Bovine Serum 
Albumin (BSA) was immobilized on channel 2 (CH 2) using standard amine coupling 
chemistry with a running buffer of 20 mM HEPES, pH 7.4, 100 mM NaCl.  
400 mM 3-(N,N-dimethylamino)propyl-N-ethylcarbodiimide (EDC) and 100 mM 
N-hydroxysuccinimide (NHS) was mixed in a 1:1 proportion and injected using the ‘fast 
inject’ option over CH 3-2 for 7 min at a flow rate of 25 µL/min. 50 µg/ml BSA in 10 mM 
Acetate, pH 4.5, was injected using ‘fast inject’ over CH 3-2 at 10 µL/min to give a density 
of 3500 RU and served as the reference surface. 1M Ethanolamine, pH 8.5, was injected 
for 4 min at a flow rate of 25 µL/min over CH 3-2 to cap any activated esters.  
400 mM EDC and 100 mM NHS, mixed in a 1:1 proportion was then injected using 
‘fast inject’ over CH 1 for 7 min at 25µL/min followed by an injection of 48 µg/ml Grb2 
SH2 in 10 mM Acetate, pH 5, over CH 1 at 10 µL/min to give a density matching that of 
the reference BSA surface. 1 M Ethanolamine, pH 8.5, was injected for 4 min at a flow 
rate of 25 µL/min over CH 1 to cap any activated esters. 
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After immobilization, the buffer was switched to 50 mM HEPES, pH 7.4, 150 mM 
NaCl, 0.05% Tween 20, 5% DMSO and primed 5X followed by equilibration at a flow rate 
of 75 µL/min for at least 30 min. Serial dilutions of analytes were prepared manually 
(typically 5 µM high concentration and 7 subsequent 2 or 3-fold dilutions) in a buffer that 
was carefully matched to the running buffer. The analyte was injected over the two flow 
cells at a flow rate of 75 µL/min and at a temperature of 25 oC. The analyte-ligand complex 
was allowed to associate for 60 seconds and dissociate for 90 seconds (compound 3.15) or 
120 seconds (compound 3.10). 3.15 dissociated back to baseline within the dissociation 
time stated above and did not require regeneration. A 12 second injection of 1M 
Ethanolamine, pH 8.5, at a flow rate of 75 µL/min was used to regenerate the surface after 
the 120 second dissociation time of 3.10. Each assay was preceded by priming the system, 
5 buffer blanks, and 8 DMSO standards. Additionally 1 buffer blank was injected after 
every 4 injections of the analyte. Each analyte was tested in triplicate (from low to high 
concentration) with a data collection rate of 10 Hz. The data were fit to 1:1 interaction 
model using global data analysis with the Qdat™ analysis software package from SensiQ®. 
The Kd values obtained from kinetic parameters matched those obtained from an 
equilibrium analysis and the curves for it are presented in Appendix B.  
Isothermal Titration Calorimetry 
ITC experiments were performed in duplicate using a Nano-ITC equilibrated at 25 
°C. Between experiments involving the same ligand, the sample cell was thoroughly rinsed 
with water followed by the final HEPES dialysis buffer. The injection apparatus was 
cleaned sequentially with water and methanol and dried. The sample cell was cleaned with 
a 0.01% SDS solution between experiments involving different ligands. Typically, after an 
initial injection of 0.2 µL, 19 x 20 µL injections of ligand were made into the sample cell. 
Raw data were integrated, background heats for injecting ligand into buffer were 
subtracted, and binding parameters were measured using the NanoAnalyze™ software. Ka 
and ΔH°. ΔG° was calculated indirectly from Ka by applying the modified Arrhenius 
equation, ΔG° = –RTlnKa. ΔS° was calculated by applying the Gibbs relationship ΔG° = 
ΔH° – TΔS°.  
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CHAPTER IV 
Development of Substrate-Competitive Irreversible Inhibitors of Akt1 
4.1. Abstract 
 Targeting the substrate-binding site of a protein kinase offers many advantages over 
targeting the ATP-binding site, most significantly obtaining a higher degree of selectivity. 
The nature of the substrate-binding site typically requires the development of peptidic 
inhibitors that lack potency and suffer from poor cell permeability and stability. In this 
study, the challenges of developing small molecule inhibitors of the substrate-binding site, 
have been overcome by covalently inhibiting the target Akt1 kinase. A library of 110 
fragments with electrophiles appended to them was screened against Akt1 yielding 8 hits 
with greater than 75% inhibition at a single screening concentration of 100 µM. Follow-up 
dose-response curves confirmed 1 hit with an IC50 value of 9 µM. Limited modifications 
of the hit resulted in compound 4.4 with an IC50 of  4.4 µM. Docking studies have enabled 
a proposed binding mode for the molecule and set the stage for the further development of 
a selective substrate-competitive irreversible inhibitor of Akt1.   
4.2. Inhibitors Targeting the ATP-Binding Site of Kinases 
518 protein kinases encoded in the human genome collectively catalyze the transfer 
of the γ-phosphate of ATP to a serine, threonine or tyrosine residue of substrate proteins or 
peptides. The result is the phosphorylation of up to one-third of intracellular proteins or 
20,000 distinct phosphoproteins, with a remarkable degree of specificity for their 
substrates.1-2  
Despite the high degree of complexity required for an individual protein kinase to 
phosphorylate only a particular substrate, all 518 protein kinases share a remarkably similar 
overall architecture, termed the kinase fold.3 This fold is comprised of an N-lobe primarily 
comprised of β-sheets and a C-lobe made up of α-helices. The common substrate for all 
protein kinases is ATP, which binds to a deep hydrophobic cleft formed between the N-
lobe and C-lobe with high nanomolar to low micromolar potencies.4 The ability of all 
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members of this large superfamily of proteins to bind to ATP, stems from a highly 
conserved ATP-binding pocket, making exquisitely selective inhibitor development 
challenging.  
All current FDA-approved kinase inhibitors target the ATP-binding site of kinases. 
The spectrum of selectivity displayed by these inhibitors ranges from inhibiting 2% to over 
90% of the kinome. No FDA-approved kinase inhibitor or inhibitor in clinical development 
that targets the ATP-binding site has demonstrated efficacy against a single kinase only.5 
Off-target kinase inhibition can have several undesirable consequences. The primary 
concern is toxicity that can impact patient compliance, and in certain cases, be life-
threatening as described in the case of Ponatinib in Chapter II. Furthermore, studies by our 
lab, and by others, have demonstrated that inhibition of kinases that have an anti-oncogenic 
role could lead to increased tumor growth. c-Abl, which in its fused Bcr-Abl form is the 
molecular cause of Chronic Myelogenous Leukemia (CML), is anti-oncogenic in the case 
of breast cancer.6 Most c-Src inhibitors currently in development for treating breast cancer 
also inhibit c-Abl with high potency and this inhibition may be counterproductive. 
Similarly, the off-target inhibition of wild-type Raf can lead to dimerization and 
paradoxical activation of downstream pathways leading to increased cell growth and 
proliferation.7-8  
Pan-kinase inhibitors, may not be necessarily disadvantageous from a drug 
development standpoint, where targeting multiple kinases involved in tumorigenesis may 
be preferred over targeting a single kinase. Only a select group of cancers such as CML 
and Gastrointestinal Stromal Tumors (GIST) are driven by a single oncogenic kinase (Bcr-
Abl and c-Kit, respectively). The vast majority of cancers, particularly those with high 
mortality rates, can escape inhibition of a single kinase through mutations in the active site 
of the targeted kinase, activation of surrogate kinases that can take over the activity of the 
targeted kinase, and the activation of multiple, redundant kinase signaling pathways. In 
such cases, developing inhibitors targeting multiple kinases or using cocktails of highly 
selective inhibitors would be preferable.9 Nevertheless, identifying the appropriate kinases 
to be targeted for a particular cancer remains challenging and can only be achieved through 
the development of inhibitors with a narrow spectrum of selectivity.  
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Developing chemical probes to study the biological function of a particular protein 
kinase is particularly challenging when targeting the ATP-binding site. Even when ‘drug-
like’ properties and pharmacokinetics of a small molecule are disregarded, selectivity is 
difficult to achieve within any particular family of protein kinases due to a high degree of 
sequence similarity between family members. KB-4-102, an ATP-competitive probe 
developed in our lab, is one of the most selective c-Src inhibitors reported to date inhibiting 
only 8 of 96 kinases tested.6 It does, however, inhibit 3 (Lck, Fgr, Yes) of the 6 Src Family 
Kinases (SFKs) it was tested against with a Kd value within 10-fold of that observed for c-
Src. Consequently, its use as a probe to delineate the biological function of individual SFKs 
is limited.  
4.3. Inhibitors Targeting the Substrate-Binding Site of Kinases 
 The specificity of a protein kinase for its substrate is achieved through multiple 
mechanisms including differing peptide-binding sites, sub-cellular localization, and 
recruitment via additional domains of the protein kinase. The lack of conservation within 
the peptide-binding site offers an avenue for the development of selective inhibitors for a 
protein kinase. For example, Lck and c-Src mentioned above, share over 85% sequence 
identity within the ATP-binding site, but about a 60% sequence identity with the peptide 
binding site, enabling the development of inhibitors that can selectively target c-Src over 
Lck. Using this approach, a bi-substrate probe developed in our lab was observed to inhibit 
only 2 (c-Src and c-Yes) of 213 kinases tested eliminating any affinity for Lck and Fgr.10 
Despite the potential for selectivity that can be gained through targeting the 
substrate-binding site of a kinase, over 99% of reported kinase inhibitors target the ATP-
binding site. This asymmetry can be attributed to the fact that while ATP binds to a deep, 
well-defined, hydrophobic pocket within the kinase, a peptide or protein substrate typically 
binds to a shallow, open, and extended surface (Figure 4.1). The tractable nature of the 
ATP-binding site enabled the rapid development of adenosine analogs and identification 
of adenosine-like heterocyclic hits through high-throughput screening libraries. In 
comparison, the nature of the peptide-substrate binding site dictates inhibitors targeting it 
have a large surface area enabling them to make multiple contacts with so-called hot-spots 
within the binding site.11 Additionally a lack of structural data – fewer than 15 kinases have 
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been crystallized with a ligand bound to the peptide-binding site - has compounded the 
difficulty of developing substrate-competitive inhibitors.12  
Consequently, inhibitors developed to target the substrate-binding site are typically 
linear peptides based on the known biological substrate, which suffer from the 
disadvantages of poor cell-permeability and stability, resulting in low in cellulo efficacy. 
Small molecule substrate-competitive inhibitors, which could circumvent the problems of 
permeability and stability, are challenging to develop due to the abovementioned nature of 
the substrate-binding site. When successful, small molecule substrate-competitive 
inhibitors can have several advantages over their ATP-competitive counterparts. In 
addition to the aforementioned selectivity disadvantage, ATP-competitive inhibitors 
Figure 4.1. Surface representation of Akt1 (PDB 3MV5). An 
ATP-competitive inhibitor (purple) is bound in a deep 
hydrophobic pocket and a peptide substrate (yellow) is bound 
over a shallow extended interface.   
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contend with high intracellular levels of ATP in the millimolar range. As a result, 
biochemical potency usually does not correlate well with in cellulo potency. Substrate-
competitive inhibitors, on the other hand must contend with low micromolar levels of 
endogenous substrate resulting in a higher degree of correlation between biochemical and 
cellular efficacy. For example, SCI, a small molecule substrate-competitive c-Src inhibitor, 
developed in our lab, demonstrated a 3 to 20-fold selectivity for c-Src over all other SFKs 
and showed a cellular to biochemical efficacy ratio of 1. This was a marked improvement 
over an ATP-competitive c-Src inhibitor, PP2, which despite its higher potency, lacked any 
selectivity among SFKs and displayed a cellular to biochemical efficacy ratio of 44.4 
4.4. Covalent Inhibitors of Protein Kinases 
 Recently, there has been a resurgence in the use of covalent inhibitors to target 
protein kinases. Once avoided for their purported off-target effects ascribed to their 
intrinsic reactivity, covalent kinase inhibitors such as Afatinib and Ibrutinib, have 
demonstrated good efficacy with minimal toxicity.  
Covalent inhibition offers an additional selectivity filter for targeting protein 
kinases. Work by Frank Kwarcinski in our lab, has demonstrated that a reversible inhibitor 
based on a promiscuous scaffold can be converted to a selective inhibitor by strategically 
appending an electrophile that could react with a non-conserved cysteine on the desired 
enzyme.13 While most such efforts have been directed towards the development of ATP-
competitive inhibitors, covalent inhibition is uniquely suited for the development of 
substrate-competitive inhibitors. In addition to being able to leverage selectivity by 
targeting a non-conserved cysteine, covalently targeting the substrate-binding site could 
circumvent the problem of low affinity associated with substrate-competitive inhibitors. 
Since covalent inhibition is irreversible and time-dependent, a low affinity inhibitor could 
elicit the same response in cellulo as a high-affinity reversible ATP-competitive inhibitor. 
Few kinases are observed to have a cysteine in their activation loop, which upon 
activation, is immediately proximal to the substrate-binding site of the kinase. One of these 
kinases, Akt1, has been previously targeted at the Cys310 residue of the activation loop 
with toxic quinone-containing antibiotics14-15 and peptidomimetic inhibitors.16-17 Given the 
importance of Akt1 in cancer cell-signaling (described in Section 4.5), we sought to 
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develop covalent substrate-competitive inhibitors using a fragment-based lead discovery 
(FBLD) approach.        
4.5. Akt1 as a Therapeutic Target in Cancer 
The Akt kinases are a sub-family of the AGC family of kinases, and consist of 3 
isoforms – Akt1 (PKBα), Akt2 (PKBβ), and Akt3 (PKBγ). All 3 isoforms have an N-
terminal Pleckstrin Homology (PH) domain, a central catalytic serine/threonine kinase 
domain, and a C-terminal regulatory domain.18 The Akt kinases form an integral part of 
the phosphoinositide 3-kinase (PI3K) signaling pathway, which in turn is connected to, yet 
distinct from, growth factor signaling pathways.  
Growth factor stimulation of cells leads to the activation of growth factor receptors, 
membrane localization of adaptor proteins, and the activation of Ras by the exchange of 
GDP with GTP. Details of Ras activation through growth factor stimulation have been 
discussed in Chapters I and III.  The PI3Ks are heterodimers of regulatory and catalytic 
subunits. On receptor activation, the regulatory subunit of PI3K can bind directory to 
phosphotyrosine residues on receptors or to adaptor proteins, while the catalytic subunit 
can bind directly to Ras. Consequently, the plasma membrane lipid, phosphatidylinositol-
4,5-bisphosphate is phosphorylated to phosphatidylinositol-3,4,5-trisphosphate 
(PI(3,4,5)P3),  by the kinase activity of PI3K.
19  
The Akt kinases are recruited to the membrane through the association of their PH 
domain with PI(3,4,5)P3. Membrane localization results in the phosphorylation and 
activation of Akt and is negatively regulated by the phosphatase PTEN. Activated Akt 
kinases  have been known to phosphorylate more than 50 downstream substrates involved 
in a variety of cellular processes, including proliferation, survival, motility, angiogenesis, 
and glucose homeostasis.20 Mutational loss of PTEN activity leading to constitutively 
activated Akt kinases have been observed in a variety of human malignancies.21-22  
While there may be a large degree of overlap between the substrates of Akt kinases, 
the different isoforms are not believed to be redundant as certain substrates are known to 
be specifically phosphorylated by a particular isoform.20 Akt3, which is restricted to 
neuronal tissue and the testes,20 probably has the greatest variability in substrates owing to 
its tissue-specific expression. Consistent with this hypothesis, knockout of Akt3 in mice, 
resulted in a 20% decrease in brain size but had no role in the maintenance of carbohydrate 
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metabolism.23 The individual roles of Akt1 and Akt2, however, have been difficult to 
delineate and while many cancer types have shown a dependence on both these isoforms, 
certain evidence suggests that they may have opposing roles in tumorigenesis within the 
context of particular breast cancers.24  
A lack of isoform-specific inhibitors has compounded the problem of delineating 
the role of different isoforms. Current strategies generally rely on the use of ATP-
competitive small molecules such as MKK-2206 or GSK690693 which are pan-Akt 
inhibitors or on gene knockouts which can result in the activation of redundant pathways. 
Of the three isoforms, only Akt1 has a cysteine residue in the activation loop adjacent to 
the substrate binding site. The development of a covalent substrate-competitive inhibitor 
of Akt1 could enable isoform-specificity and could be useful as a tool for the exploration 
of the therapeutic potential of targeting Akt kinases in cancer. 
4.6. Fragment Screening of an Electrophile Library 
 FBLD is now widely used in both academia and industry. Over 30 current 
clinical candidates, including a few approved drugs, have been identified and developed 
through fragment-based methods.25 The approach entails screening a relatively small 
library, members of which are typically less than 300 Da in molecular weight, against the 
target of interest. The small size of the fragments, generally enables the identification of 
weak hits with affinity values in the high micromolar to millimolar range. The low affinity 
hits can then be combined or grown to yield stronger hits. The fragment universe in terms 
of chemical space is many orders of magnitude smaller than that of molecules with a 
molecular weight greater than 300 Da. Thus, a library, substantially smaller than that used 
in traditional high throughput screening (HTS) efforts, can sample a larger proportion of 
chemical space resulting in a higher hit rate.26 This method is particularly well suited for 
the identification of substrate-competitive inhibitors which would require a greater 
sampling of chemical diversity for the successful development of potent inhibitors.  
Our target of interest, Akt1, was screened against a 110-member library of 
electrophilic-containing fragments using a Z’-LYTE™ activity assay and enabled the 
identification of covalent substrate-competitive fragments.  
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Z’-LYTE™ Activity Assay 
 Fragment screening is typically accomplished through biophysical methods such as 
NMR and SPR. While these are powerful tools to identify weak affinity binders, they do 
not necessarily identify compounds that can inhibit the activity of the protein of interest. 
Monitoring the activity of an enzyme in the presence of fragments provides for the direct 
identification of inhibitors of the enzyme. In the case of kinases, activity assays can lead to 
the identification of both ATP-competitive as well as substrate-competitive inhibitors. This 
problem is particularly exacerbated in the case of HTS where the flat, heterocyclic 
composition of library members leads to a biased identification of ATP-competitive 
inhibitors.12 We believed that screening our library with an ATP concentration (75 µM) 
equal to that of its Km against Akt1, coupled with the lack of a cysteine residue in the hinge 
binding region, would be sufficient to bias our effort to the identification of substrate-
competitive inhibitors.  
 The commercially available Z’-LYTE™ kinase assay kit was used to screen our 
fragment library. The Z’-LYTE™ kinase assay is a coupled assay system, and consists of 
an optimized Akt1 substrate peptide which bears a coumarin-based fluorophore on one end 
and a fluorescein-based fluorophore on the other, which together form a FRET pair. In the 
primary reaction, Akt1 catalyzes the phosphorylation of a serine residue on the 
fluorophore-labelled substrate peptide. In the secondary reaction, the addition of a site-
specific protease, cleaves the non-phosphorylated peptides, resulting in a disruption of 
FRET between the coumarin and fluorescein moieties. Uncleaved, phosphorylated 
peptides maintain their FRET signal. Fully active, uninhibited Akt1 would result in a high 
proportion of phosphorylated peptide with a high FRET signal. Inhibition of Akt1, would 
result in a higher proportion of cleaved peptides, thereby suppressing the FRET signal. A 
ratiometric method is used to calculate percent activity of the enzyme on inhibition.  
Fragment Library 
A commercially available fragment library obtained from InFarmatik Inc. was used 
in the screen. Structures of library members are provided in Appendix C. The average 
molecular weight of the library members was 235 Da that comprised of aliphatic and 
aromatic anilines capped to give an acrylamide electrophile, which could be used to screen 
for covalent inhibitors.  
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Screening Results 
The library was screened at a single concentration of 100 µM, and percent inhibition of 
Akt1 activity was measured after a 1 hour incubation period (Figure 4.2). The Z-factor, a 
measure of the statistical quality of an assay, was 0.62, indicating that the assay was robust 
with a large dynamic range and small data variability.27 A mean inhibition value of 16% 
was obtained with a standard deviation of ±25%. A cut-off value of 66% (2 standard 
deviations from the mean) yielded a 9% hit rate. 
The top 10 hits obtained are shown in Figure 4.3. The hits obtained had certain 
conserved scaffolds such as indoles, furans, pyrrolidine, and cyclopentyl groups, 
suggesting that combining fragments would be feasible. Full dose-response curves were 
obtained to confirm the 10 hits and to identify inhibitors with low micromolar potencies.  
Only 2 compounds, EL-1119 and EL-1061, were confirmed as inhibitors of Akt1 with IC50 
values of 9 µM and 76 µM respectively. Re-synthesis and re-testing of EL-1119 
(subsequently labelled compound 4.1) provided an IC50 value of 9.7 ± 3.7 µM in line with 
the original value obtained from a follow-up of the fragment screen. A close analog of 
Figure 4.2. Fragment screening results of Akt1. The green line indicates the 66% cut-off 
value used to determine positive hits.  
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compound 4.1 containing a meta-aniline was appended with an electrophile to give 
compound 4.2, but displayed a loss in potency with an IC50 of 48 ± 2µM. 
 
4.7. Modification of the Electrophile 
Varying the electrophilic group can have large differences on potency either due to 
the innate reactivity of the electrophile or due to spatial positioning of the electrophile 
relative to the nucleophilic cysteine on the enzyme. Two additional electrophiles, an α-
chloroacetamide and a vinylsulfonamide were appended in place of the acrylamide of 
compound 4.1, to give compounds 4.3 and 4.4, respectively.  
The Taunton group has demonstrated the ability of β-aryl-α-cyanoacrylamide based 
electrophiles to reversibly and covalently bind to cysteine nucleophiles.28 The reversibility 
of the reaction is thought to arise from the increased acidity of the α-proton which can be 
easily de-protonated at physiological pH leading to dissociation of the cysteine adduct. 
While reversible covalent inhibitors do not necessarily present any biological advantage 
Figure 4.3. Top 10 hits obtained from the fragment screen 
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over irreversible inhibitors, the synthetic route used to make them offers an opportunity for 
the late-stage introduction of chemically diverse moieties at the β-aryl position. To explore 
if diversification at the β-aryl position was feasible, a β-phenyl-α-cyanoacrylamide moiety 
was appended on to the starting fragment to give compound 4.5.  
As shown in Table 4.1, the α-chloroacetamide containing compound 4.3 showed 
about a 10-fold loss in potency suggesting that the distance between the electrophilic 
carbon and reactive cysteine is a key determinant of potency. Compound 4.4 with a vinyl 
sulfonamide electrophile was found to have the greatest potency with an IC50 value of 4.4 
µM (a slight improvement compared to the acrylamide containing 4.1). Lastly, the 
reversible covalent analog, compound 4.5, had an IC50 value greater than 100 µM 
suggesting that the binding site does not permit bulky groups at the β position of the 
electrophile.   
Table 4.1. IC50 values obtained on varying the 
electrophile. 
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4.8. Proposed Binding Mode 
In the absence of a crystal structure, to gain insight into the binding mode of the 
fragment, compound 4.1 was docked into the substrate site of Akt1 using an online docking 
server, CovalentDock Cloud. This program is built on top of the source code of the widely 
used Autodock, with the ability to estimate the free energy change on covalent linkage 
formation.29 The proposed binding mode is as shown in Figure 4.4 with a covalent bond 
formed with Cys310 of Akt1, and the phenylindole ring oriented away from the peptide 
binding site. Its close proximity to the phenylalanine of the overlaid GSK3β peptide could 
enable further growth of the fragment.  
4.9. Conclusions 
Substrate-competitive inhibitors of protein kinases can present certain advantages 
over ATP-competitive inhibitors such as greater selectivity and the requirement to compete 
against lower levels of endogenous substrate. These type of inhibitors, however, remain 
drastically underexplored due to their lack of potency, screening tools, and structural 
information available. Covalently targeting the substrate binding site offers an attractive 
solution for countering issues related to poor potency of inhibitors as these show a time 
Figure 4.4. Proposed binding mode of compound 4.1 to Akt1 
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dependent inactivation of the enzyme. A fragment screen of electrophile-containing 
fragments against the serine/threonine kinase Akt1 enabled the identification of compound 
4.1 with low micromolar potency. Further modification of the electrophile led to the 
identification of compound 4.4 with a vinyl sulfonamide electrophile and a slight 
improvement in potency over 4.1. The lack of a cysteine residue in the activation loop of 
Akt2 and Akt3, could make compound 4.4 uniquely suited for discerning the functional 
role of Akt1 within the PI3K signaling pathway. 
4.10. Materials and Methods 
General Synthetic Methods 
Unless otherwise noted, all reagents were obtained via commercial sources and 
used without further purification. Dichloromethane (DCM) was dried over alumina under 
a nitrogen atmosphere. 1H and 13C NMR spectra were measured with a Varian MR400, 
Varian VNMRS 500, or Inova 500 spectrometer. Mass Spectrometry (HRMS) was carried 
out by the University of Michigan Mass Spectrometry Facility (J. Windak, director). 
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Synthetic Protocols 
Synthesis of 4.1 - 4-(1H-indol-2-yl)aniline (25 mg, 0.12 mmol) and triethylamine (20.1 μL, 
0.144 mmol) were added to acetonitrile (1.2 ml) and the solution was cooled in an ice-
water bath. Acryloyl chloride (11.7 μL, 0.144 mmol) was then added and the reaction was 
monitored by TLC (50% EtOAc/Hex). Complete conversion to product was observed after 
1.5 h at which point 12 ml water was added to give a suspension. The mixture was stirred 
for 10 min, filtered, and the residue dried. The crude residue was purified using reverse-
phase (C18) column chromatography on a Biotage Isolera One system (linear gradient 30% 
MeCN/H2O → 100% MeCN) to give 17.6 mg (56% yield) of compound 4.1 as an off-
Scheme 4.1. Synthesis of compound 4.1-4.6 
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white solid. 1H NMR (500 MHz, DMSO-d6) δ 11.46 – 11.42 (m, 1H), 10.25 (s, 1H), 7.81 
(d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.1 Hz, 
1H), 7.09 – 7.02 (m, 1H), 6.96 (t, J = 7.4 Hz, 1H), 6.81 (d, J = 2.1 Hz, 1H), 6.45 (dd, J = 
16.9, 10.1 Hz, 1H), 6.27 (dd, J = 16.9, 1.9 Hz, 1H), 5.76 (dd, J = 10.1, 1.9 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 163.57, 138.74, 137.97, 137.47, 132.25, 129.16, 127.92, 
127.44, 125.91, 121.76, 120.27, 120.03, 119.75, 111.60, 98.46. HRMS-ESI (m/z): [M + 
H]+ calcd for C17H14N2O, 263.1179; found x.x.  
 
Synthesis of 4.2 - 3-(1H-indol-2-yl)aniline (50 mg, 0.24 mmol) and triethylamine (35.2 μL, 
0.252 mmol) were added to DCM (2.5 ml) and the solution was cooled in an ice-water 
bath. Acryloyl chloride (35.2 μL, 0.252 mmol) was then added and the reaction was 
monitored by TLC (50% EtOAc/Hex). Complete conversion to product was observed after 
3 h at which point 0.5 ml methanol was added to quench excess acryloyl chloride. The 
solvents were removed in vacuo and the crude product was purified using reverse-phase 
(C18) column chromatography on a Biotage Isolera One system (linear gradient 30% 
MeCN/H2O → 100% MeCN) to give 17.5 mg (28% yield) of compound 4.2 as a cream-
white solid. 1H NMR (500 MHz, DMSO-d6) δ 11.54 (s, 1H), 10.26 (s, 1H), 8.19 (d, J = 1.9 
Hz, 1H), 7.55 (t, J = 8.2 Hz, 3H), 7.42 (t, J = 8.8 Hz, 2H), 7.10 (t, J = 7.5 Hz, 1H), 7.00 (t, 
J = 7.4 Hz, 1H), 6.80 (d, J = 2.0 Hz, 1H), 6.49 (dd, J = 16.9, 10.1 Hz, 1H), 6.31 (dd, J = 
17.0, 1.9 Hz, 1H), 5.80 (dd, J = 10.1, 1.9 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 
163.72, 139.93, 138.05, 137.62, 133.27, 132.30, 129.81, 128.99, 127.53, 122.07, 120.84, 
120.54, 119.84, 119.17, 116.78, 111.86, 99.17. HRMS-ESI (m/z): [M + H]+ calcd for 
C17H14N2O, 263.1179; found 263.1176.  
 
Synthesis of 4.3 - 4-(1H-indol-2-yl)aniline (150 mg, 0.72 mmol) and triethylamine (120.6 
μL, 0.864 mmol) were added to acetonitrile (7.2 ml) and the solution was cooled in an ice-
water bath. Chloroacetyl chloride (68.7 μL, 0.864 mmol) was then added and the reaction 
was monitored by TLC (50% EtOAc/Hex). Complete conversion to product was observed 
after 1.5 h at which point 70 ml water was added to give a suspension. The mixture was 
stirred for 10 min, filtered, and the residue dried. The crude residue was purified using 
reverse-phase (C18) column chromatography on a Biotage Isolera One system (linear 
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gradient 30% MeCN/H2O → 100% MeCN) to give 39.7 mg (19% yield) of compound 4.3 
as an orange-brown solid. 1H NMR (500 MHz, DMSO-d6) δ 11.46 (s, 1H), 10.41 (s, 1H), 
7.82 (d, J = 8.1 Hz, 2H), 7.68 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 7.8 Hz, 1H), 7.38 (d, J = 8.1 
Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 6.81 (s, 1H), 4.28 (s, 2H). 13C 
NMR (126 MHz, DMSO-d6) δ 165.08, 138.17, 137.84, 137.49, 129.15, 128.29, 125.97, 
121.82, 120.32, 120.08, 119.78, 111.62, 98.59, 44.07. HRMS-ESI (m/z): [M + H]+ calcd 
for C16H13ClN2O, 285.0789; found 285.0787.  
 
Synthesis of 4.4 - 4-(1H-indol-2-yl)aniline (80 mg, 0.384 mmol) and triethylamine (64.2 
μL, 0.46 mmol) were added to acetonitrile (3.8 ml) and the solution was cooled in an ice-
water bath. 2-chloro-1-ethanesulfonyl chloride (48 μL, 0.46 mmol) was then added and the 
reaction was monitored by TLC (50% EtOAc/Hex). Complete conversion to product was 
observed after 1.5 h. The volatile components were removed in vacuo and the residue was 
purified using reverse-phase (C18) column chromatography on a Biotage Isolera One 
system (linear gradient 40% MeCN/H2O → 80% MeCN/H2O) to give 31 mg (27% yield) 
of compound 4.4 as an off-white solid. 1H NMR (500 MHz, DMSO-d6) δ 11.47 – 11.42 
(m, 1H), 10.13 (s, 1H), 7.82 – 7.75 (m, 2H), 7.50 (dt, J = 8.0, 0.9 Hz, 1H), 7.37 (dq, J = 
8.1, 1.0 Hz, 1H), 7.25 – 7.19 (m, 2H), 7.07 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 6.98 (ddd, J = 
7.9, 7.0, 1.1 Hz, 1H), 6.87 – 6.78 (m, 2H), 6.15 (d, J = 16.4 Hz, 1H), 6.06 (d, J = 9.9 Hz, 
1H). 13C NMR (126 MHz, DMSO-d6) δ 137.71, 137.65, 137.47, 136.79, 129.11, 128.19, 
128.05, 126.28, 121.80, 120.39, 120.29, 119.76, 111.61, 98.57. HRMS-ESI (m/z): [M + 
H]+ calcd for C16H14N2O2S, 299.0849; found 299.0848.  
 
Synthesis of 4.6 - 4-(1H-indol-2-yl)aniline (100 mg, 0.48 mmol) was dissolved in DMF 
and cooled in an ice-water bath. Cyanoacetic acid (49 mg, 0.576 mmol), N-
methylmorpholine (127 μL, 1.15 mmol) and EDC.HCl (110.4 mg, 0.576 mmol) were then 
added to the solution and the reaction was monitored by TLC (50% EtOAc/Hex). After 3h, 
the reaction was diluted with 20 ml water and extracted with EtOAc (3x). The combined 
organic layers were washed with sat. NaHCO3, brine, dried over sodium sulfate, and 
evaporated in vacuo. The crude product was purified using reverse-phase (C18) column 
chromatography on a Biotage Isolera One system (linear gradient 30% MeCN/H2O → 
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100% MeCN) to give 48 mg (36% yield) of compound 4.6. 1H NMR (401 MHz, DMSO-
d6) δ 11.43 (d, J = 2.1 Hz, 1H), 10.38 (s, 1H), 7.83 – 7.76 (m, 2H), 7.63 – 7.54 (m, 2H), 
7.47 (d, J = 7.8 Hz, 1H), 7.42 – 7.31 (m, 1H), 7.04 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 6.99 – 
6.90 (m, 1H), 6.79 (d, J = 2.1 Hz, 1H), 3.90 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 
161.46, 138.04, 137.78, 137.46, 129.10, 128.29, 125.98, 121.81, 120.29, 119.91, 119.76, 
116.33, 111.60, 98.57, 27.23. HRMS-ESI (m/z): [M + H]+ calcd for C17H13N3O, 276.1131; 
found 276.1130. 
 
Synthesis of 4.5 – Compound 4.6 (40 mg, 0.145 mmol), benzaldehyde (14.7 μL, 0.144 
mmol), and piperidine (14.2 μL, 0.144 mmol) were added to isopropanol and the solution 
was heated at 60 °C and monitored by TLC (70% EtOAc/Hex). Complete conversion to 
product was observed after 2 h and the reaction mixture was cooled to room temperature 
and purified directly using reverse-phase (C18) column chromatography on a Biotage 
Isolera One system (linear gradient 50% MeCN/H2O → 100% MeCN) to give compound 
4.5 as an orange solid. 1H NMR (500 MHz, DMSO-d6) δ 11.53 – 11.48 (m, 1H), 10.54 (s, 
1H), 8.32 (s, 1H), 8.04 – 7.98 (m, 2H), 7.91 – 7.84 (m, 2H), 7.81 – 7.75 (m, 2H), 7.67 – 
7.57 (m, 3H), 7.52 (d, J = 7.8 Hz, 1H), 7.39 (dq, J = 8.3, 0.9 Hz, 1H), 7.09 (ddd, J = 8.2, 
7.1, 1.2 Hz, 1H), 6.99 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.87 (dd, J = 2.2, 0.9 Hz, 1H). 13C 
NMR (100 MHz, DMSO-d6) δ 160.92, 151.33, 137.90, 137.75, 137.50, 132.97, 132.33, 
130.51, 129.75, 129.11, 128.72, 125.80, 121.89, 121.22, 120.35, 119.80, 116.63, 111.64, 
107.70, 98.77. HRMS-ESI (m/z): [M + H]+ calcd for C24H17N3O, 364.1444; found 
364.1444. 
Spectral Data 
1H and 13C NMR Spectra for all compounds synthesized in this chapter are shown 
in Appendix C. 
General Biochemical Methods 
Full length Akt1 was purchased from Life Technologies™ and used according to 
the manufacturer’s instructions. The fragment library was obtained from InFarmatik Inc., 
and stored as 50 mM stock solutions in DMSO at -80 °C. The Z’-LYTE™ activity assay 
kit was purchased from Life Technologies™ and used according to the protocol provided. 
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Black, low-volume Corning 384-well plates were used for the TR-FRET assay and data 
was obtained using a Biotek Synergy 4 plate reader.  Curve fitting was performed using 
GraphPad Prism 4 software. 
 
Fragment Screening Protocol and Determination of IC50 
 All reagents were diluted in 1.33X kinase buffer. Reaction volumes of 10 µL were 
used in 384-well plates. Briefly, 2.5 µL of the fragment stock solution (10 mM in DMSO) 
was added to each well followed by the addition of 5 µL of a 2X Akt1 (20.3 nM)/peptide 
(4 µM) mixture. The reactions were initiated with 2.5 µL 4X ATP (300 µM), mixed and 
incubated in the dark at room temperature for 1h. Each well had a final concentration of 10 
nM Akt1, 2 µM substrate peptide, 100 µM inhibitor, 75 µM ATP in 1X kinase buffer (50 
mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA). 5 µL of development 
reagent was then added and the assay mixture was mixed and further incubated in the dark 
for 1 h. The reaction was terminated by the addition of a stop reagent and the FRET signal 
was measured using an excitation wavelength of 400 nm and emission wavelengths of 445 
nm and 520 nm. The appropriate positive and negative controls were used according to the 
protocol provided. The emission ratio at the two wavelengths was used to calculate the 
percent phosphorylation. The equation % Phosphorylation = (Emission Ratio x F100%)-
C100%/ (C0% - C100%) + [Emission Ratio x (F100% - F0%) was used where C100% is the average 
coumarin emission signal of the 100% phosphorylation control, C0% is the average 
coumarin emission signal of the 0% phosphorylation signal, F100% is the average fluorescein 
emission signal of the 100% phosphorylation control, and F0% is the average fluorescein 
emission signal of the 0% phosphorylation control. For IC50 values determination, 3-fold 
dilutions of compounds (typically 100, 33.3, 11.1, 3.7, 1.23, 0.41, 0.137, and 0.045 µM) 
were used. The structures of the fragments in the library and all representative IC50 curves 
are reported in Appendix C. 
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Representative IC50 curve for compound 4.4 
 
Avg IC50 = 4.4 ± 0.3 μM 
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CHAPTER V 
Conclusions and Future Directions 
5.1 Abstract 
 Studies presented in this dissertation have focused on developing inhibitors of 
phospho-signaling proteins involved in cancer pathogenesis. Each chapter has conclusions 
detailing the lessons learned during the development of inhibitors for a particular protein 
in question. This chapter puts into focus these lessons at a macroscopic level and 
investigates whether they could be applicable elsewhere. Furthermore, it provides a 
roadmap that could be exploited for the development of inhibitors of other de-regulated 
proteins involved in cancer. 
5.2 Development of a Selective Inhibitor of Abl Kinase  
The success of Imatinib in the treatment of CML spurred intensive research into 
the development of inhibitors of other kinases involved in the progression of certain 
cancers. Despite over a decade of research in the field, few inhibitors have proved to be as 
selective as Imatinib despite advances in kinase profiling technology1 and a more complete 
understanding of the conformational plasticity of kinases.2 While second and third 
generation inhibitors of Bcr-Abl have led to improvements in efficacy and the ability to 
target Imatinib-resistant CML, none of these inhibitors have a spectrum of selectivity better 
than or even comparable to that of Imatinib. Consequently, substantial effort has been put 
into understanding the reasons for the selectivity of Imatinib. The predominant model of 
selectivity, put forth by the Maly group3, and expanded upon by the Kern group4-5, 
hypothesizes that the kinked P-loop of c-Abl offers protection to Imatinib against solvent 
molecules. This hydrophobic shell around Imatinib prevents its solvation and increases its 
potency for c-Abl. Closely related kinases such as c-Src do not have a kinked P-loop 
resulting in an energetic penalty for solvation resulting in lower potency. This hypothesis 
has been substantiated, at least in part, by the development of hydrophilic inhibitors that 
are equipotent for c-Abl and c-Src, and through mutational and kinetic analysis of the two 
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enzymes.3-4 No current approved drug or inhibitor in development, however, has exploited 
this hypothesis for the development of selective inhibitors of c-Abl.  
We sought to validate the above-stated hypothesis and utilize it to develop selective 
inhibitors of c-Abl. Our studies have detailed the development of a series of DFG-out 
inhibitors with hinge-binding groups ranging from hydrophilic to highly hydrophobic. The 
hydrophilic hinge-binding groups led to lower levels of selectivity when comparing c-Src 
and c-Abl. Compound 2.3, which bears a very hydrophobic naphthyl group, was found to 
be moderately potent against c-Abl (Ki = 155 nM) but completely eliminated potency for 
c-Src (Ki > 27 μM). The fact that a hinge-region group without an H-bond donor or acceptor 
atom could retain potency for c-Abl validated the hypothesis that a kinked P-loop must be 
an important determinant for potency and selectivity for c-Abl. The addition of a single N-
atom in compound 2.4, led to a 400-fold increase in potency for c-Abl (Kd = 380 pM). 
While compound 2.4 did lead to an increase in potency for c-Src (Ki = 216 nM) too, the 
570-fold difference in potency for c-Abl versus c-Src, was comparable to that of Imatinib. 
Furthermore, compound 2.4 unlike 2.3, had the ability to inhibit the Y253F P-loop mutant 
of c-Abl resulting in it being chosen as the lead compound for further profiling and cell 
assays. A kinome-wide profile of compound 2.4 revealed it to be the most selective c-Abl 
inhibitor capable of inhibiting the T315I gatekeeper mutation known to date. Cell assays 
demonstrated it to be a very potent inhibitor of a variety of cell lines with minimal toxicity 
to healthy cells. Further in vivo studies of compound 2.4 are necessary and underway for 
establishing the utility of compound 2.4 in the treatment of CML.  
5.3 Optimizing Entropic Gains for Developing Inhibitors of Specific Kinases 
Inhibitors are typically developed for enthalpic gains through optimization of H-
bond donor and acceptor atoms. Our results indicate that counter to conventional wisdom, 
optimizing entropic gains by increasing the hydrophobicity of a compound seems to be a 
superior strategy for developing potent and selective inhibitors of c-Abl. The 400-fold 
increase in potency for c-Abl of 2.4 versus 2.3 corresponds to a free energy change of about 
-15 kJ, caused solely due to the introduction of a single N-atom. Further studies utilizing 
Isothermal titration calorimetry (ITC) could allow the delineation of the enthalpic and 
entropic components of this decrease in overall free energy. Furthermore, the molar heat 
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capacity change calculated through ITC could aid in the understanding of the de-solvation 
of each of these compounds on binding to c-Abl.  
A general strategy to optimize entropic gains of a compounds has been 
underexplored in the development of kinase inhibitors. Such a strategy could be very useful 
in the development of inhibitors of other kinases with a kinked P-loop. Only 6 other kinases 
– Ack1, AurA, c-Met, FGFR1, MAP4K4, and p38 - have been observed to have a kinked 
P-loop in their X-ray crystal structures.6 These kinases could be particularly well-suited for 
targeting with inhibitors comprising of a hydrophobic hinge-binding group. Despite 
crystallographic evidence being limited to these 6 kinases, it does not suggest that all other 
kinases have an extended P-loop. Indeed, even in the case of c-Abl, an analysis of available 
X-ray crystal structures showed that only 9 of 25 complexes displayed a kinked P-loop.6 
Comparing the results of profiling of compound 2.4 with AST-487 shows that only 3 
kinases, AurC, Axl, and LRRK2 are targets of 2.4 but not of AST-487. Given that the only 
significant difference between the two compounds is that 2.4 has a hydrophobic hinge 
binding group, it could well suggest that these kinases can potentially adopt a kinked P-
loop and the strategy described above could be complementary for developing inhibitors 
of these kinases.  
5.4 N-Scan of the Core Scaffold Yields Substantial Differences in Selectivity 
Within the quinoline series of compounds, the position of the quinoline N-atom (in 
compound 2.5) and replacement of the connecting O-atom with an NH-group (in 
compound 2.6) leads to a dramatic loss in potency for c-Src. X-ray crystallography could 
be useful in determining the exact binding mode of each of these compounds and could aid 
in the understanding of the vast differences in selectivity. Such single-atom changes have 
been seldom explored in kinase inhibitors and could lead to a wide variability in selectivity 
while utilizing the same scaffold.  
The Y253F mutant of c-Abl is believed to be resistant to Imatinib due to a partial 
opening of the P-loop.3 Compound 2.6 shows a 10-fold loss in potency for Y253F c-Abl 
suggesting that its potency for c-Abl is strongly determined by the formation of a 
hydrophobic shell around it. It is, however, expected to bind to Lck potently like most other 
c-Abl inhibitors, despite the extended P-loop of Lck. A bulky group appended onto the 
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quinoline moiety of compound 2.6 (Figure 5.1) could cause a steric clash with the kinked 
P-loop of c-Abl, thereby preventing binding. An opening up of its P-loop to accommodate 
such a moiety would also result in a lower potency as is observed for compound 2.6. 
However, such a bulky group could be accommodated within the extended P-loop of Lck, 
thus providing an avenue for developing a selective inhibitor of Lck that does not bind c-
Abl or any Src-family kinase. 
 
5.5 Leveraging the Selectivity of 2.4 for Developing Irreversible Inhibitors 
Comparing the selectivity profile of Imatinib to compound 2.4 in Table 2.4, it 
becomes apparent that most of the additional targets of the latter compound are due to its 
ability to bypass bulky gatekeeper residues. Thus, the advantage of being able to inhibit all 
clinically relevant mutants of c-Abl, is a slight disadvantage in terms of selectivity. Despite, 
a slight expansion in potent targets, compound 2.4 remains a highly selective compound 
kinome-wide. Consequently, its selectivity and potency can be potentially leveraged to 
develop the core scaffold into a potent inhibitor of one of its off-targets.  
A multiple sequence alignment of the 33 high and low affinity targets of compound 
2.4 reveals the distribution of residues which interact with the compound (Figure 5.2). The 
sterile kinase Lok is the only target containing a cysteine residue (corresponding to I293 in 
c-Abl) within the hydrophobic back-pocket of the kinase and Axl contains one just outside 
this pocket (corresponding to V289 in c-Abl). Modifying the type-II tail of compound 2.4 
with a Michael acceptor such as an acrylamide could provide potent irreversible inhibitor 
of Lok and Axl. Such a strategy could not be used on currently available c-Abl scaffolds 
Figure 5.1. Potential development of Lck-selective inhibitors 
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as both these kinases possess non-threonine gatekeeper residues making selective targeting 
problematic.  
Figure 5.2. Multiple sequence alignment of the targets of compound 2.4. Black arrows 
indicate sites of interaction with the inhibitor. The red boxes displays the distribution of 
residues corresponding to V289 and I293 in c-Abl.  
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5.6 Utilizing Conformational Constraint to Stabilize Turns Other than α-Helices 
 Conformational constraint has, in recent years, been used with great success for 
stabilizing peptides binding to a protein target in an α-helical conformation. Such α-helices 
are stabilized specifically through an i→i+4 or an i→i+7 peptide staple.7 Stabilization of 
alternate secondary structures such as a β or γ-turn, however, has been seldom explored 
outside the use of unnatural amino acids to stabilize such turns. In our studies, we sought 
to examine the effects of macrolactamization on the binding of the consensus sequence 
peptide pYVNV to the SH2 domain on the adaptor protein Grb2. Through a systematic 
enlargement of the macrocycle we were able to obtain the optimal macrocycle size for 
binding to Grb2 SH2. Our lead compound 3.5, with an i→i+6 lactam bond had an IC50 
value of 700 nM in a fluorescence polarization assay. Replacement of the phosphotyrosine 
residue with a non-hydrolyzable phosphonomethyl phenylalanine in compound 3.10 led to 
a potent inhibitor with a Kd value of 212 nM and a GI50 of 19 μM in K562 cells.  
The potency of compound 3.10 is believed to be derived from lowering the entropic 
penalty of binding to the protein. Martin and co-workers have examined the effect of local 
and global conformational constraint on the binding of peptides to a number of different 
proteins including Grb2.8-10 Extensive analysis of the enthalpic and entropic components 
of binding through isothermal titration calorimetry led them to the conclusion that 
conformational constraint does not always lower the entropic penalty of binding. They 
believed that constraining a peptide could lower the enthalpy of binding, which 
paradoxically, could increase the entropic cost of binding termed as enthalpy-entropy 
compensation. According to the laws of thermodynamics, however, provided that 
enthalpies of a constrained and unconstrained peptide are identical, conformational 
constraint must lower the entropic cost of binding. We believed that the effect observed by 
Martin and co-workers was due to the fact that they used a non-optimal macrocycle. Thus, 
we sought to investigate the enthalpic and entropic components of our optimized lead 
compound 3.10. An ITC comparison of 3.10 with its unconstrained analog 3.16 
unambiguously demonstrated that the change in enthalpies of the two compounds were 
identical and the increase in potency for compound 3.10 was solely driven through a 
lowered entropic penalty of binding.  
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Additionally, surface plasmon resonance studies demonstrated that the constrained 
and linear analogs had nearly equal kon rates, but compound 3.10 had a significantly slower 
koff suggesting that conformational constraint could be utilized to increase the residence 
time of a ligand.  
An often overlooked advantage of peptide cyclization is that it increases stability 
of the compound toward cellular proteases. Incubation of the cyclic peptide 3.10 and linear 
peptide 3.16 with a protease such as elastase, which cuts at the C-terminal end of valine 
and glycine residues, could offer insight into the stability of the cyclic variant in 
comparison to its linear counterpart. 
5.7 Utilizing Cyclic Peptides to Identify Inhibitors of Other SH2 Domains 
The Grb2 SH2 domain is only one of 18 SH2 domain that has a preference for an 
Asparagine residue in the pY+2 position. Other SH2 domains with such a preference 
include GRAP, GADS, GRB7/10/14, Fer/Fes, and Tensin 1/2. An Asn at pY+2 residue, 
however, does not guarantee binding in a β-turn conformation and could instead involve 
binding in an extended conformation.11-12 Even within those SH2 domains that bind to their 
peptide partner with a β-turn, they do so through a variety of mechanisms. In the case of 
Grb2, GRAP, and GADS, a β-turn is enforced by Trp residue on the EF1 loop of the protein 
surface (nomenclature based on the structure of the Src SH2 domain). The Grb7 family of 
SH2 domains lack a Trp residue at EF1. They do, however, have a longer EF loop, the 
backbone of which blocks the extension of the phosphotyrosine containing peptide. Lastly, 
the Fes SH2 has a Thr residue on the BG loop which effectively enforces a β-turn similar 
to that enforced by Trp in Grb2.11-12 The different mechanisms of enforcing a β-turn suggest 
that cyclic peptides of different sizes would be needed to inhibit each of these domains. 
Our library of cyclic peptides could be utilized for optimizing the macrocycle size, and 
further development of the optimized macrocycles could yield potent inhibitors for each of 
these SH2 domains. Based on our studies with the SH2 domain of Grb2, such optimized 
peptides would be predicted to have a lower entropic cost of binding and thus a higher 
potency compared to their linear analogs. 
95 
 
5.8 N-Methylation to Increase Permeability of Cyclic Peptides 
Our studies were primarily directed towards using biophysical methods to develop 
potent inhibitors of Grb2 SH2. While our lead compound showed efficacy in a CML cell 
line, further development would be needed for the practical use of this peptide in cell 
assays. N-methylation of the backbone amide bonds is known to be an effective strategy 
for increasing hydrophobicity of a cyclic peptide. Additionally, N-methylation enforces the 
formation of intramolecular H-bonds which in turn could further increase cell permeability. 
The conventional means for the development of N-methylated cyclic peptides is a 
systematic and iterative process in which each of the amide bonds is methylated and cell 
permeability is determined.13 Such a process is extremely cumbersome and could require 
the synthesis and testing of a large number of N-methyl variants of compound 3.10.  
It has been known for a decade that the temperature dependence of the chemical 
shift of an amide proton (as determined by variable temperature TOCSY NMR) is 
indicative of the hydrogen bonding of such a proton.14 Cierpack et al. determined that 
amide protons in a protein with a chemical sift temperature coefficient (∆δ/∆T) of <-4.6 
ppb/K are typically water-exposed, while those that are ≥ -4.6 ppb/K are involved in intra-
molecular H-bonds.14 A recent report demonstrated the utility of this information in the 
development of N-methylated cyclic peptides.15 Amides with a chemical shift temperature 
coefficient of <-4.6 ppb/K were methylated leading to N-methylated cyclic peptides with 
a substantial increase in cell permeability and bioavailability.15 Such a process could be 
utilized for N-methylation of compound 3.10 and could be useful in increasing the cell 
permeability of the compound through a minimally iterative process. 
5.9 Substrate Competitive Irreversible Inhibitors of Akt1 
Our studies involved developing irreversible inhibitors of Akt1 that bind to the 
substrate binding site of the enzyme. These inhibitors were identified through a fragment 
screen and optimized by changing the electrophile. The most potent inhibitor 4.4 with an 
IC50 value of 4.4 μM could be useful in a cellular context despite its micromolar potency 
due to its irreversible nature and through competition with low levels of endogenous 
substrate. Akt1 was is not the only kinase containing a surface-exposed cysteine residue 
near the substrate binding pocket. Other kinases such as AurC, CAMK4, and MELK 
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contain a similarly placed cysteine residue and the methods described in this dissertation 
could be generally applicable to any of these kinases.16  
The assay described in the development of compound 4.4 is an end-point assay and 
cannot be used to measure initial rates of binding thus precluding the availability of 
valuable kinetic data. A continuous fluorescence quenching assay for Akt1 as described by 
Imperiali group17 could circumvent this problem and could be used to measure time 
dependent IC50 values of compounds 4.1-4.5 and could thus be used to measure the rate of 
inactivation (kinact) of each of these compounds.  
5.10 Conclusions 
In almost half a decade since the ‘war on cancer’ was declared, substantial progress 
has been made in developing safe and effective therapies for specific cancers. The research 
leading up to these developments has led to an increased understanding of the molecular 
causes and incredible complexity of signaling pathways involved in cancer. This 
understanding has been coupled with the realization that the treatment of different cancers 
would require targeted therapy towards a variety of proteins involved in oncogenesis.  The 
studies presented in this dissertation have highlighted the difficulties and challenges in 
developing inhibitors of phospho-signaling proteins involved in cancer. Each of the 
proteins have been targeted through different methodologies involving a variety of 
rationales as dictated by the nature of the binding site. In addition to a rationale for 
developing potent inhibitors for c-Abl, Grb2, and Akt1, the work presented in this 
dissertation provides a primer could be generally applicable for developing inhibitors of 
several other kinases and SH2-domain containing proteins.  
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APPENDIX A 
Analytical Data and Supplemental Information for Chapter II 
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A.1. Spectral Data for Compounds 2.1-2.25 
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A.2 Analytical Data for Determination of Ki Values 
Compound 2.1 
 
 
Average Ki = 28.4 ± 10 nM (wt Src), Titrates enzyme (IC50 ̴ 30 nM) for wt, T315I, and 
Y253F Abl  
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Compound 2.2 
 
Average Ki = 36.3 ± 19 nM (wt Src), Titrates enzyme (IC50 ̴ 30 nM) for wt, T315I, and 
Y253F Abl  
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Compound 2.3 
 
 
 
Average Ki = 155 ± 5 nM (wt Abl), 119 ± 62 nM (T315I Abl), No inhibition <9 μM (Y253F 
Abl), <27 μM (wt Src) 
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Compound 2.4 
 
Average Ki  > 12 nM (wt Src), Titrates enzyme (IC50 ̴ 30 nM) for wt, T315I, and Y253F 
Abl  
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Compound 2.5 
 
Average Ki = 2 ± 0.2 nM (wt Abl), 4.3 ± 0.3 nM (T315I Abl), 6.1 ± 0.5 nM (Y253F Abl), 
12.5 ± 0.3 μM (wt Src).  
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Compound 2.6 
 
 
Average Ki  = 1.66 ± 0.02 nM (wt Abl), 2.1 ± 1.3 nM (T315I Abl), 50 ± 1.7 nM (Y253F 
Abl), 4.2 ± 2 μM (wt Src).  
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A.3 KinomeScan™ Data for Compound 2.4 
DiscoveRx Gene Symbol Entrez Gene Symbol Percent Control 
Compound 
Concentratio
n (nM) 
AAK1 AAK1 100 40 
ABL1(E255K)-phosphorylated ABL1 30 40 
ABL1(F317I)-nonphosphorylated ABL1 0 40 
ABL1(F317I)-phosphorylated ABL1 16 40 
ABL1(F317L)-nonphosphorylated ABL1 0.3 40 
ABL1(F317L)-phosphorylated ABL1 14 40 
ABL1(H396P)-nonphosphorylated ABL1 0.45 40 
ABL1(H396P)-phosphorylated ABL1 19 40 
ABL1(M351T)-phosphorylated ABL1 15 40 
ABL1(Q252H)-nonphosphorylated ABL1 2 40 
ABL1(Q252H)-phosphorylated ABL1 31 40 
ABL1(T315I)-nonphosphorylated ABL1 0.2 40 
ABL1(T315I)-phosphorylated ABL1 4.6 40 
ABL1(Y253F)-phosphorylated ABL1 30 40 
ABL1-nonphosphorylated ABL1 0.85 40 
ABL1-phosphorylated ABL1 12 40 
ABL2 ABL2 15 40 
ACVR1 ACVR1 100 40 
ACVR1B ACVR1B 79 40 
ACVR2A ACVR2A 95 40 
ACVR2B ACVR2B 89 40 
ACVRL1 ACVRL1 100 40 
ADCK3 CABC1 96 40 
ADCK4 ADCK4 85 40 
AKT1 AKT1 100 40 
AKT2 AKT2 91 40 
AKT3 AKT3 98 40 
ALK ALK 76 40 
ALK(C1156Y) ALK 100 40 
ALK(L1196M) ALK 91 40 
AMPK-alpha1 PRKAA1 75 40 
AMPK-alpha2 PRKAA2 88 40 
ANKK1 ANKK1 75 40 
ARK5 NUAK1 91 40 
ASK1 MAP3K5 85 40 
ASK2 MAP3K6 100 40 
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AURKA AURKA 92 40 
AURKB AURKB 56 40 
AURKC AURKC 17 40 
AXL AXL 23 40 
BIKE BMP2K 86 40 
BLK BLK 29 40 
BMPR1A BMPR1A 94 40 
BMPR1B BMPR1B 100 40 
BMPR2 BMPR2 94 40 
BMX BMX 94 40 
BRAF BRAF 75 40 
BRAF(V600E) BRAF 58 40 
BRK PTK6 100 40 
BRSK1 BRSK1 98 40 
BRSK2 BRSK2 98 40 
BTK BTK 84 40 
BUB1 BUB1 93 40 
CAMK1 CAMK1 93 40 
CAMK1D CAMK1D 90 40 
CAMK1G CAMK1G 100 40 
CAMK2A CAMK2A 100 40 
CAMK2B CAMK2B 100 40 
CAMK2D CAMK2D 100 40 
CAMK2G CAMK2G 100 40 
CAMK4 CAMK4 100 40 
CAMKK1 CAMKK1 100 40 
CAMKK2 CAMKK2 100 40 
CASK CASK 100 40 
CDC2L1 CDK11B 80 40 
CDC2L2 CDC2L2 94 40 
CDC2L5 CDK13 50 40 
CDK11 CDK19 11 40 
CDK2 CDK2 81 40 
CDK3 CDK3 100 40 
CDK4-cyclinD1 CDK4 95 40 
CDK4-cyclinD3 CDK4 100 40 
CDK5 CDK5 94 40 
CDK7 CDK7 59 40 
CDK8 CDK8 13 40 
CDK9 CDK9 89 40 
CDKL1 CDKL1 76 40 
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CDKL2 CDKL2 1.8 40 
CDKL3 CDKL3 22 40 
CDKL5 CDKL5 100 40 
CHEK1 CHEK1 100 40 
CHEK2 CHEK2 87 40 
CIT CIT 100 40 
CLK1 CLK1 40 40 
CLK2 CLK2 100 40 
CLK3 CLK3 87 40 
CLK4 CLK4 32 40 
CSF1R CSF1R 4.6 40 
CSF1R-autoinhibited CSF1R 85 40 
CSK CSK 95 40 
CSNK1A1 CSNK1A1 98 40 
CSNK1A1L CSNK1A1L 100 40 
CSNK1D CSNK1D 95 40 
CSNK1E CSNK1E 91 40 
CSNK1G1 CSNK1G1 100 40 
CSNK1G2 CSNK1G2 100 40 
CSNK1G3 CSNK1G3 84 40 
CSNK2A1 CSNK2A1 90 40 
CSNK2A2 CSNK2A2 84 40 
CTK MATK 57 40 
DAPK1 DAPK1 100 40 
DAPK2 DAPK2 97 40 
DAPK3 DAPK3 100 40 
DCAMKL1 DCLK1 88 40 
DCAMKL2 DCLK2 96 40 
DCAMKL3 DCLK3 100 40 
DDR1 DDR1 0.45 40 
DDR2 DDR2 15 40 
DLK MAP3K12 97 40 
DMPK DMPK 74 40 
DMPK2 CDC42BPG 100 40 
DRAK1 STK17A 100 40 
DRAK2 STK17B 97 40 
DYRK1A DYRK1A 100 40 
DYRK1B DYRK1B 57 40 
DYRK2 DYRK2 90 40 
EGFR EGFR 65 40 
EGFR(E746-A750del) EGFR 82 40 
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EGFR(G719C) EGFR 89 40 
EGFR(G719S) EGFR 86 40 
EGFR(L747-E749del, A750P) EGFR 60 40 
EGFR(L747-S752del, P753S) EGFR 65 40 
EGFR(L747-T751del,Sins) EGFR 92 40 
EGFR(L858R) EGFR 70 40 
EGFR(L858R,T790M) EGFR 96 40 
EGFR(L861Q) EGFR 82 40 
EGFR(S752-I759del) EGFR 83 40 
EGFR(T790M) EGFR 71 40 
EIF2AK1 EIF2AK1 92 40 
EPHA1 EPHA1 100 40 
EPHA2 EPHA2 71 40 
EPHA3 EPHA3 62 40 
EPHA4 EPHA4 80 40 
EPHA5 EPHA5 95 40 
EPHA6 EPHA6 81 40 
EPHA7 EPHA7 100 40 
EPHA8 EPHA8 23 40 
EPHB1 EPHB1 94 40 
EPHB2 EPHB2 87 40 
EPHB3 EPHB3 100 40 
EPHB4 EPHB4 98 40 
EPHB6 EPHB6 92 40 
ERBB2 ERBB2 73 40 
ERBB3 ERBB3 96 40 
ERBB4 ERBB4 100 40 
ERK1 MAPK3 100 40 
ERK2 MAPK1 93 40 
ERK3 MAPK6 96 40 
ERK4 MAPK4 79 40 
ERK5 MAPK7 79 40 
ERK8 MAPK15 70 40 
ERN1 ERN1 97 40 
FAK PTK2 91 40 
FER FER 100 40 
FES FES 99 40 
FGFR1 FGFR1 86 40 
FGFR2 FGFR2 90 40 
FGFR3 FGFR3 96 40 
FGFR3(G697C) FGFR3 100 40 
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FGFR4 FGFR4 95 40 
FGR FGR 91 40 
FLT1 FLT1 38 40 
FLT3 FLT3 0.9 40 
FLT3(D835H) FLT3 14 40 
FLT3(D835Y) FLT3 15 40 
FLT3(ITD) FLT3 8 40 
FLT3(K663Q) FLT3 1.4 40 
FLT3(N841I) FLT3 0.2 40 
FLT3(R834Q) FLT3 5.6 40 
FLT3-autoinhibited FLT3 100 40 
FLT4 FLT4 53 40 
FRK FRK 50 40 
FYN FYN 97 40 
GAK GAK 100 40 
GCN2(Kin.Dom.2,S808G) EIF2AK4 75 40 
GRK1 GRK1 100 40 
GRK4 GRK4 100 40 
GRK7 GRK7 95 40 
GSK3A GSK3A 91 40 
GSK3B GSK3B 74 40 
HASPIN GSG2 96 40 
HCK HCK 44 40 
HIPK1 HIPK1 94 40 
HIPK2 HIPK2 89 40 
HIPK3 HIPK3 78 40 
HIPK4 HIPK4 56 40 
HPK1 MAP4K1 61 40 
HUNK HUNK 88 40 
ICK ICK 100 40 
IGF1R IGF1R 100 40 
IKK-alpha CHUK 52 40 
IKK-beta IKBKB 57 40 
IKK-epsilon IKBKE 93 40 
INSR INSR 64 40 
INSRR INSRR 100 40 
IRAK1 IRAK1 88 40 
IRAK3 IRAK3 99 40 
IRAK4 IRAK4 99 40 
ITK ITK 98 40 
JAK1(JH1domain-catalytic) JAK1 67 40 
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JAK1(JH2domain-pseudokinase) JAK1 100 40 
JAK2(JH1domain-catalytic) JAK2 88 40 
JAK3(JH1domain-catalytic) JAK3 54 40 
JNK1 MAPK8 86 40 
JNK2 MAPK9 44 40 
JNK3 MAPK10 92 40 
KIT KIT 1.5 40 
KIT(A829P) KIT 15 40 
KIT(D816H) KIT 75 40 
KIT(D816V) KIT 81 40 
KIT(L576P) KIT 1.5 40 
KIT(V559D) KIT 0.55 40 
KIT(V559D,T670I) KIT 5.5 40 
KIT(V559D,V654A) KIT 11 40 
KIT-autoinhibited KIT 100 40 
LATS1 LATS1 97 40 
LATS2 LATS2 91 40 
LCK LCK 5 40 
LIMK1 LIMK1 100 40 
LIMK2 LIMK2 100 40 
LKB1 STK11 100 40 
LOK STK10 0.05 40 
LRRK2 LRRK2 24 40 
LRRK2(G2019S) LRRK2 54 40 
LTK LTK 75 40 
LYN LYN 40 40 
LZK MAP3K13 100 40 
MAK MAK 85 40 
MAP3K1 MAP3K1 82 40 
MAP3K15 MAP3K15 92 40 
MAP3K2 MAP3K2 100 40 
MAP3K3 MAP3K3 100 40 
MAP3K4 MAP3K4 100 40 
MAP4K2 MAP4K2 93 40 
MAP4K3 MAP4K3 97 40 
MAP4K4 MAP4K4 69 40 
MAP4K5 MAP4K5 86 40 
MAPKAPK2 MAPKAPK2 100 40 
MAPKAPK5 MAPKAPK5 100 40 
MARK1 MARK1 100 40 
MARK2 MARK2 83 40 
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MARK3 MARK3 100 40 
MARK4 MARK4 92 40 
MAST1 MAST1 72 40 
MEK1 MAP2K1 100 40 
MEK2 MAP2K2 100 40 
MEK3 MAP2K3 92 40 
MEK4 MAP2K4 100 40 
MEK5 MAP2K5 100 40 
MEK6 MAP2K6 100 40 
MELK MELK 61 40 
MERTK MERTK 41 40 
MET MET 100 40 
MET(M1250T) MET 84 40 
MET(Y1235D) MET 79 40 
MINK MINK1 72 40 
MKK7 MAP2K7 77 40 
MKNK1 MKNK1 43 40 
MKNK2 MKNK2 3.6 40 
MLCK MYLK3 100 40 
MLK1 MAP3K9 100 40 
MLK2 MAP3K10 100 40 
MLK3 MAP3K11 100 40 
MRCKA CDC42BPA 94 40 
MRCKB CDC42BPB 89 40 
MST1 STK4 78 40 
MST1R MST1R 91 40 
MST2 STK3 69 40 
MST3 STK24 100 40 
MST4 MST4 95 40 
MTOR MTOR 95 40 
MUSK MUSK 11 40 
MYLK MYLK 100 40 
MYLK2 MYLK2 73 40 
MYLK4 MYLK4 81 40 
MYO3A MYO3A 85 40 
MYO3B MYO3B 74 40 
NDR1 STK38 78 40 
NDR2 STK38L 100 40 
NEK1 NEK1 92 40 
NEK10 NEK10 97 40 
NEK11 NEK11 94 40 
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NEK2 NEK2 100 40 
NEK3 NEK3 100 40 
NEK4 NEK4 92 40 
NEK5 NEK5 100 40 
NEK6 NEK6 85 40 
NEK7 NEK7 100 40 
NEK9 NEK9 100 40 
NIK MAP3K14 89 40 
NIM1 MGC42105 95 40 
NLK NLK 75 40 
OSR1 OXSR1 70 40 
p38-alpha MAPK14 35 40 
p38-beta MAPK11 89 40 
p38-delta MAPK13 70 40 
p38-gamma MAPK12 20 40 
PAK1 PAK1 97 40 
PAK2 PAK2 100 40 
PAK3 PAK3 36 40 
PAK4 PAK4 100 40 
PAK6 PAK6 100 40 
PAK7 PAK7 96 40 
PCTK1 CDK16 99 40 
PCTK2 CDK17 65 40 
PCTK3 CDK18 97 40 
PDGFRA PDGFRA 34 40 
PDGFRB PDGFRB 3.7 40 
PDPK1 PDPK1 100 40 
PFCDPK1(P.falciparum) CDPK1 50 40 
PFPK5(P.falciparum) MAL13P1.279 100 40 
PFTAIRE2 CDK15 95 40 
PFTK1 CDK14 97 40 
PHKG1 PHKG1 90 40 
PHKG2 PHKG2 100 40 
PIK3C2B PIK3C2B 89 40 
PIK3C2G PIK3C2G 69 40 
PIK3CA PIK3CA 87 40 
PIK3CA(C420R) PIK3CA 65 40 
PIK3CA(E542K) PIK3CA 97 40 
PIK3CA(E545A) PIK3CA 70 40 
PIK3CA(E545K) PIK3CA 91 40 
PIK3CA(H1047L) PIK3CA 88 40 
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PIK3CA(H1047Y) PIK3CA 58 40 
PIK3CA(I800L) PIK3CA 89 40 
PIK3CA(M1043I) PIK3CA 60 40 
PIK3CA(Q546K) PIK3CA 78 40 
PIK3CB PIK3CB 100 40 
PIK3CD PIK3CD 77 40 
PIK3CG PIK3CG 92 40 
PIK4CB PI4KB 100 40 
PIM1 PIM1 100 40 
PIM2 PIM2 95 40 
PIM3 PIM3 100 40 
PIP5K1A PIP5K1A 100 40 
PIP5K1C PIP5K1C 100 40 
PIP5K2B PIP4K2B 94 40 
PIP5K2C PIP4K2C 100 40 
PKAC-alpha PRKACA 100 40 
PKAC-beta PRKACB 69 40 
PKMYT1 PKMYT1 85 40 
PKN1 PKN1 95 40 
PKN2 PKN2 100 40 
PKNB(M.tuberculosis) pknB 71 40 
PLK1 PLK1 98 40 
PLK2 PLK2 94 40 
PLK3 PLK3 94 40 
PLK4 PLK4 88 40 
PRKCD PRKCD 98 40 
PRKCE PRKCE 100 40 
PRKCH PRKCH 100 40 
PRKCI PRKCI 89 40 
PRKCQ PRKCQ 95 40 
PRKD1 PRKD1 100 40 
PRKD2 PRKD2 73 40 
PRKD3 PRKD3 100 40 
PRKG1 PRKG1 68 40 
PRKG2 PRKG2 92 40 
PRKR EIF2AK2 100 40 
PRKX PRKX 75 40 
PRP4 PRPF4B 67 40 
PYK2 PTK2B 100 40 
QSK KIAA0999 100 40 
RAF1 RAF1 83 40 
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RET RET 5.4 40 
RET(M918T) RET 6.2 40 
RET(V804L) RET 18 40 
RET(V804M) RET 9 40 
RIOK1 RIOK1 100 40 
RIOK2 RIOK2 96 40 
RIOK3 RIOK3 93 40 
RIPK1 RIPK1 96 40 
RIPK2 RIPK2 90 40 
RIPK4 RIPK4 100 40 
RIPK5 DSTYK 96 40 
ROCK1 ROCK1 94 40 
ROCK2 ROCK2 80 40 
ROS1 ROS1 100 40 
RPS6KA4(Kin.Dom.1-N-terminal) RPS6KA4 79 40 
RPS6KA4(Kin.Dom.2-C-terminal) RPS6KA4 100 40 
RPS6KA5(Kin.Dom.1-N-terminal) RPS6KA5 100 40 
RPS6KA5(Kin.Dom.2-C-terminal) RPS6KA5 100 40 
RSK1(Kin.Dom.1-N-terminal) RPS6KA1 76 40 
RSK1(Kin.Dom.2-C-terminal) RPS6KA1 100 40 
RSK2(Kin.Dom.1-N-terminal) RPS6KA3 100 40 
RSK2(Kin.Dom.2-C-terminal) RPS6KA3 100 40 
RSK3(Kin.Dom.1-N-terminal) RPS6KA2 97 40 
RSK3(Kin.Dom.2-C-terminal) RPS6KA2 100 40 
RSK4(Kin.Dom.1-N-terminal) RPS6KA6 100 40 
RSK4(Kin.Dom.2-C-terminal) RPS6KA6 95 40 
S6K1 RPS6KB1 33 40 
SBK1 SBK1 62 40 
SGK SGK1 75 40 
SgK110 SgK110 100 40 
SGK2 SGK2 77 40 
SGK3 SGK3 100 40 
SIK SIK1 98 40 
SIK2 SIK2 54 40 
SLK SLK 93 40 
SNARK NUAK2 96 40 
SNRK SNRK 91 40 
SRC SRC 100 40 
SRMS SRMS 89 40 
SRPK1 SRPK1 64 40 
SRPK2 SRPK2 100 40 
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SRPK3 SRPK3 97 40 
STK16 STK16 98 40 
STK33 STK33 66 40 
STK35 STK35 93 40 
STK36 STK36 85 40 
STK39 STK39 90 40 
SYK SYK 100 40 
TAK1 MAP3K7 6 40 
TAOK1 TAOK1 88 40 
TAOK2 TAOK2 83 40 
TAOK3 TAOK3 83 40 
TBK1 TBK1 92 40 
TEC TEC 95 40 
TESK1 TESK1 100 40 
TGFBR1 TGFBR1 96 40 
TGFBR2 TGFBR2 100 40 
TIE1 TIE1 31 40 
TIE2 TEK 3.4 40 
TLK1 TLK1 100 40 
TLK2 TLK2 100 40 
TNIK TNIK 75 40 
TNK1 TNK1 96 40 
TNK2 TNK2 100 40 
TNNI3K TNNI3K 94 40 
TRKA NTRK1 34 40 
TRKB NTRK2 27 40 
TRKC NTRK3 55 40 
TRPM6 TRPM6 100 40 
TSSK1B TSSK1B 92 40 
TTK TTK 61 40 
TXK TXK 90 40 
TYK2(JH1domain-catalytic) TYK2 89 40 
TYK2(JH2domain-pseudokinase) TYK2 100 40 
TYRO3 TYRO3 100 40 
ULK1 ULK1 61 40 
ULK2 ULK2 91 40 
ULK3 ULK3 31 40 
VEGFR2 KDR 57 40 
VRK2 VRK2 90 40 
WEE1 WEE1 89 40 
WEE2 WEE2 100 40 
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WNK1 WNK1 95 40 
WNK3 WNK3 95 40 
YANK1 STK32A 82 40 
YANK2 STK32B 100 40 
YANK3 STK32C 96 40 
YES YES1 100 40 
YSK1 STK25 98 40 
YSK4 YSK4 96 40 
ZAK ZAK 2.6 40 
ZAP70 ZAP70 100 40 
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B.1. Peptide Synthesis and Characterization 
All peptides were synthesized on a 0.1 mmol scale manually, using standard Fmoc-
SPPS chemistry on a Rink Amide ‘Low Loading’ resin. The resin was swelled for 30 min 
in NMP prior to the first deprotection step. All steps were monitored using the Kaiser test 
and repeated if necessary. 
Fmoc Deprotection 
Fmoc deprotection was carried out using 20% (v/v) piperidine in NMP (7 ml) for 
at least 10 min at room temperature. The deprotection solution was subsequently drained 
and the resin washed with NMP (4x) before moving on to the next step. 
Coupling: 
A solution of Fmoc amino acid (0.5 mmol), HBTU (190 mg, 0.5 mmol), and DIEA 
(0.2 ml, 1.15 mmol) in NMP (4 ml) was added to the resin and mixed for at least 20 min at 
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rt. Upon completion the resin was washed with NMP (4x). For the coupling of Fmoc-
Lys(Alloc)-OH, Fmoc-Asp(OAllyl)-OH and non-natural amino acids, 0.4 mmol of the 
corresponding amino acid was used and the coupling carried out for at least 1h at room 
temperature. 
Repeat 
The above sequence of Fmoc deprotection and coupling was repeated until the 
desired amino acids had been assembled on resin. 
Allyl/Alloc Deprotection 
A solution of Pd(PPh3)4 (11.5 mg, 0.01 mmol), N,N-dimethyl barbituric acid (62 mg, 
0.4 mmol) in 7 ml DCM was added to the resin and mixed for 2 h at room temperature. 
The solution was drained and the resin washed with DCM (4x) and the step repeated.  
Cyclization 
A solution of PyBOP (208 mg, 0.4 mmol), DIEA (0.2 ml, 1.15 mmol) in 8 ml NMP 
was added to the resin and mixed for at least 1 h at rt. Longer peptides typically required 
>2 h for cyclization. The solution was drained and the resin washed with NMP (4x). 
Acetylation 
A solution of ‘Cap Mix A’ (10% acetic anhydride, 10% pyridine, 80% THF) was 
added to the resin and mixed for 20 min at rt. The solution was drained and the resin washed 
with NMP (4x) and DCM (4x). 
Cleavage 
The peptides were cleaved off the resin by incubating with a 4 ml solution of 
TFA/Water/Triisopropylsilane (95/2.5/2.5 vol ratio) for at least 1 h at room temperature 
with occasional stirring. The solution containing cleaved peptide was drained and 
evaporated in vacuo. Peptides containing protected phosphonates or difluorophosphonates 
were stirred in a solution of bromotrimethylsilane (0.5 ml) in Acetonitrile (1.5 ml) for 2 h 
and the volatiles evaporated in vacuo.  
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Purification 
Crude peptides were dissolved in DMSO (2 ml) for HPLC purification with a 
Waters© Xbridge Prep C18 column (19 x 250 mm). All peptides were purified using a 
linear gradient of Acetonitrile (5 to 95%) in Water with both solvents containing 0.1% (v/v) 
TFA at a rate of 1%/min. Fractions containing the desired product were combined and 
lyophilized.   
B.2. Analytical Data for Determination of IC50 Values 
Compound 3.1 
No inhibition >100 μM 
 
Compound 3.2 
Average IC50 = 64 ± 12 μM 
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Compound 3.3 
 
Average IC50 = 5.3 ± 1.2 μM 
 
 
Compound 3.4 
 
Average IC50 = 2.8 ± 0.4 μM 
 
 
138 
 
Compound 3.6 
 
Average IC50 = 1.99 ± 0.4 μM 
 
Compound 3.7 
 
Average IC50 = 1.4 ± 0.15 μM 
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Compound 3.8 
 
Average IC50 = 2.7 ± 0.5 μM 
 
 
 
Compound 3.9 
 
Average IC50 = 2.6 ± 0.7 μM 
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Compound 3.10 
 
Average IC50 = 0.54 ± 0.04 μM 
 
 
Compound 3.11 
 
Average IC50 = 0.9 ± 0.1 μM 
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Compound 3.12 
 
Average IC50 = 193 ± 6 μM 
 
 
 
Compound 3.13 
 
No inhibition >100 μM 
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B.3. Kd Determination Using Equilibrium Analysis on SPR 
Top – Compound 3.10 Kd = 250 nM, Bottom – Compound 3.15 Kd = 4.53 µM 
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C.1. Spectral Data for Compounds 4.1 – 4.6 
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C.2. InFarmatik Electrophile Fragment Library 
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C.3. Percent Inhibition Values from Fragment Screen 
 
 
C.4. Analytical Data for Determination of IC50 Values 
Follow-up of initial screening results 
 
 
EL-1002 23.4397 EL-1016 5.017601 EL-1029 10.40367 EL-1040 5.289309 EL-1055 12.26516
EL-1003 23.4397 EL-1018 2.560673 EL-1030 19.59164 EL-1041 1.186666 EL-1056 12.26516
EL-1004 8.261333 EL-1019 12.5301 EL-1031 14.37781 EL-1044 17.77771 EL-1057 8.798419
EL-1005 7.453818 EL-1020 3.655214 EL-1032 2.286391 EL-1046 9.066585 EL-1058 3.928205
EL-1006 -3.81408 EL-1021 6.914212 EL-1033 5.289309 EL-1047 12.5301 EL-1059 14.64079
EL-1007 9.602168 EL-1022 7.992413 EL-1034 7.184141 EL-1048 1.461988 EL-1061 79.18494
EL-1009 0.911084 EL-1023 2.286391 EL-1035 19.84982 EL-1050 1.737049 EL-1062 17.77771
EL-1010 5.289309 EL-1024 -4.37503 EL-1036 11.99997 EL-1051 18.55653 EL-1063 12.26516
EL-1011 11.73454 EL-1025 -1.85916 EL-1037 17.51762 EL-1052 14.90353 EL-1064 14.64079
EL-1012 10.93676 EL-1027 7.184141 EL-1038 1.461988 EL-1053 7.184141 EL-1065 3.655214
EL-1015 -3.81408 EL-1028 -0.47075 EL-1039 2.286391 EL-1054 6.373595 EL-1068 5.831961
EL-1069 0.635241 EL-1108 58.9909 EL-1134 7.184141 EL-1148 6.64403 EL-1164 10.67034
EL-1071 18.81567 EL-1109 15.16603 EL-1135 74.59944 EL-1151 22.16286 EL-1167 6.102905
EL-1074 -16.1155 EL-1113 5.560763 EL-1137 13.5874 EL-1152 5.560763 EL-1168 6.64403
EL-1083 114.5248 EL-1114 91.47721 EL-1140 5.017601 EL-1153 96.15066 EL-1169 97.49706
EL-1084 7.184141 EL-1115 11.46886 EL-1141 9.602168 EL-1155 11.73454 EL-1170 7.184141
EL-1086 17.51762 EL-1119 81.03707 EL-1142 3.381966 EL-1156 39.28425 EL-1171 -10.3304
EL-1092 66.26212 EL-1123 12.5301 EL-1143 -6.62959 EL-1157 6.914212 EL-1174 17.25729
EL-1098 62.76205 EL-1124 -10.3304 EL-1144 23.9488 EL-1160 18.55653 EL-1175 11.99997
EL-1104 4.473416 EL-1125 4.473416 EL-1145 2.286391 EL-1161 7.992413 EL-1176 3.10846
EL-1105 15.42828 EL-1126 5.017601 EL-1146 28.48942 EL-1162 15.16603 EL-1177 35.40783
EL-1106 102.2454 EL-1132 74.38903 EL-1147 13.32344 EL-1163 -2.13764 EL-1178 -1.30301
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Compound 4.1 
 
Avg IC50 = 9.7 ± 3.7 μM 
 
 
 
Compound 4.2 
 
Avg IC50 = 48 ± 2 μM 
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Compound 4.3 
 
Avg IC50 = 83 ± 6 μM 
 
 
 
Compound 4.4 
 
Avg IC50 = 4.4 ± 0.3 μM 
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Compound 4.5 
 
Avg IC50 = 274 ± 45 μM 
 
